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Summary 
 
An accumulation of immature myeloid progenitor cells at the expense of normal 
hematopoietic precursors characterizes the aggressive heterogeneous cancer acute myeloid 
leukemia (AML). It affects the bone marrow and peripheral blood leading to defects in 
myeloid cell function. (1) The median age of patients with AML is 67 years and the side 
effects associated with chemotherapy available today can often not be tolerated by this 
subgroup of patients. (2) Thus, new alternative therapeutic strategies are needed. Valproic 
acid (VPA) has shown an anti-leukemic effect in 20% of AML patients. The beneficial effect 
on survival in the Brown Norwegian Myeloid Leukemia (BNML) syngeneic rat leukemia 
model when treated with the compound was previously investigated and the 
phosphoproteomic study revealed differentially expressed proteins following VPA treatment. 
(3) The expression of hexokinase 1 (HK1) and hypoxanthine phosphoribosyltransferin 1 
(HPRT1) was reduced by VPA. These proteins are inhibited by the drugs Lonidamine (LND) 
and Mycophenolate mofetil (MMF), respectively, (4, 5) and were for that reason explored for 
their anti-leukemic effect and in combination with VPA to enhance AML patients’ 
responsiveness. The ability of MMF to induce cell growth inhibition in three human AML cell 
lines was assessed and the cooperation of VPA and LND to reduce cell proliferation by 
synergism was revealed by WST-1 proliferation based assay, Hoechst 33342 dsDNA staining 
and Annexin-V/PI flow cytometric analysis. Signaling pathways were investigated by 
Western blot, and a pilot study in NOD/scid/gamma (NSG) mice was performed for 
estimating the maximum tolerated dose (MTD) of LND.  
 
The combination studies of VPA with LND or MMF are novel in AML. Novel agents are 
hoped for that they will augment the current chemotherapy available for AML patients to 
overcome drug resistance pathways, and to eventually improve the outcomes for those 
patients. The observations made may aid in the identification of targeted treatment with 
combination therapy for individual AML patients. This thesis demonstrates the use of 
metabolically interfering drugs for a dose-dependent suppression of human AML cell lines 
and the subsequent viability assays.   
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1. Introduction 
 
Acute myeloid leukemia (AML) is an aggressive heterogeneous cancer of the peripheral 
blood and the bone marrow, represented by a clonal expansion and accumulation of immature 
myeloid progenitor cells (blasts). (1) This loss of normal hematopoietic proliferation and 
differentiation leads to defects in myeloid cell function resulting in anemia, increased 
bleeding, higher infection risk, as well as organ infiltration of leukemic blasts. (1) Intensive 
chemotherapy consists most often of 7 days standard doses cytarabine, and 3 following days 
of anthracycline, also known as the 7 + 3 day regimen. The triphosphate derivative of the 
antimetabolite cytarabine inhibits DNA polymerase, whereas anthracyclines are cytotoxic 
antibiotic compounds by direct action on DNA. (6) Other chemotherapeutic agents are usually 
incorporated to the 7+3 regimen and followed by courses of consolidation chemotherapy or 
allogeneic stem cell transplantation (SCT). (7) The 7+3 regimen of cytarabine and the 
anthracycline daunorubicin has since 1973 been standard therapy of AML. (8)Age is a major 
determinant of outcome in AML patients following treatment. The median age of patients 
with AML at diagnosis is 67 years, presenting the most common leukemia in adults. The age-
adjusted population incidence is 17.5 per 100 000 for people 65 or older, compared to 1.8 
people in 100 000 for those younger than 65 years. (2, 9) Increasing age is associated with 
decreased immune-responsiveness that makes older patients tolerate infections to lesser 
extent. Slower drug clearance observed in older AML patients may contribute to increased 
chemotherapy toxicity. (10) And other factors influencing the aging population can be that 
they are more likely to have comorbidities and more adverse cytogenetics is also observed 
with increased age. (11) 
 
In the late 1970 when the development of new drugs for treating leukemia took place, the 5-
year overall survival was as low as 6.2% for patients in all races, sexes and all ages. This 
percentage increased to 25.8% in the year of 2010 according to The National Institute of 
Health: SEER Cancer Statistics. (2) However, when considering the age at diagnosis, the 
statistics changes considerably. From the year of 2004 to 2010, patients younger than 45 years 
of age had a 5-year relative survival of 55.6%, whereas the numbers are only 5.6% for 
patients aged 65 years and above. (2) It is therefore evident for the need of new therapy 
aiming this group of patients.  
P a g e  | 10 
 
10 
 
1.1 Diagnosis and Classification 
Acute myeloid leukemia needs to be diagnosed accurately to distinguish it from 
myelodysplastic syndromes (MDS) and lymphatic leukemia, as these diseases have great 
differences in prognosis as well as therapeutic strategies and effectiveness of therapy. (12) 
Procedures in the initial diagnosis include complete blood count (CBC) and peripheral blood 
smear, bone marrow aspiration (marrow) and biopsy (bone and marrow), immunophenotyping 
and cytogenetic analysis or reverse transcription polymerase chain reaction (RT-PCR) 
analysis to investigate gene fusions and somatically acquired mutations. (13) The diagnostic 
tests provide information allowing classification if the malignancies into subgroups relevant 
for treatment option or prognosis. Two classification systems of AML exist; the first 
developed by the French-American-British (FAB) Cooperative group and the more recent and 
generally accepted World Health Organization (WHO) classification system. (13) The FAB 
classification accounts mainly for morphological characteristics analyzed by cytochemistry 
and immunophenotyping. These are still important in the WHO classification, which in 
addition is based on genetic abnormalities and clinical characteristics (Table 1).  According to 
WHO a percentage of 20 or more of leukemic blasts in the peripheral blood or bone marrow is 
required for the diagnosis of AML. However, patients with the cytogenetic abnormalities; 
RUNX1-RUNX1T1 (t(8;21)(q22;q22)), CBFB-MYH11 (inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22)), PML-RARA (t(15;17)(q22;q12) are always considered to have AML, 
disregarding the percentage of blasts. (13, 14) 
 
Tabel 1. The 4
th
 edition WHO classification of Acute Myeloid Leukemia, updated in 2008 
AML with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22), RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;p22); CBFB-MYH11 
Acute promyelocytic leukemia with t(15;17)(q22;q12);PML-RARA 
AML with t(9;11)(p22;q23)MLLT3-MLL 
AML with t(6:9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3.3)(q21;26.2); RPN1-EVl1 
AML (megakaryoblastic) with t(1:22)(p13;q13); RBM15-MKL1 
AML with mutated NPM1* 
AML with mutated CEBPA* 
AML with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
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Acute myeloid leukaemia , Not Other Specified 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic and monocytic leukaemia 
Acute erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid prolierations related to Downs syndrome 
Transient abnormal myelopoiesis 
Myeloid leukaemia associated with Downs syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
Table revised from. (14) * Provisional entieties. 
1.2 Molecular Pathogenesis of Acute Myeloid Leukemia 
Knudson (15) proposed a two-hit hypothesis explaining the generation of the pathogenesis in 
AML from different genotypes. These genotypes involve the cooperation of gene 
rearrangements and mutations falling into two broad groups; class I mutations leading to a 
proliferative and survival advantage to the leukemic blasts, and class II mutations impairing 
differentiation. Additionally, recently a new class of leukemogenic genes comprising 
epigenetic regulation has been shown to play an important role in AML and suggests a 
deficiency of fulfilment in the two-hit hypothesis. (16, 17) 
Initial leukocyte counts, co-morbidity and patient age are important risk assessment factors. 
However, cytogenetic changes in AML represent the most powerful prognostic factor 
regardless of age. (13) More than 50 % of AML cases are identified to have recurrent 
chromosomal rearrangements, (18) and risk stratification can be helpful in guiding the design 
of new therapeutic strategies. One well known characterized example is t(15;17)(q22;q21) 
encoding fusion of the promyeloid leukemia (PML) gene with the retinoic acid receptor  α 
(RARα) gene. This fusion creates a hybrid protein that impairs the normal differentiation of 
promyelocytic cells. (19) The drug all-trans retinoic acid (ATRA) targets this class II mutated 
fusion protein directly to promote differentiation, and patients with this translocation are 
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therefore associated with a favorable prognosis. (20) Younger adult patients are classified 
according to three basic groups based on prognosis-associated cytogenetic aberrations; 
favorable, intermediate and adverse. Older patients with an age of 60 ≥ are frequently 
associated with decreasing incidence of favorable versus an increase in adverse cytogenetics. 
(21, 22) Cytogenetic normal AML (CN-AML) patients form the largest sub-group (40-50 %) 
in AML (13) but do also show a great heterogeneity of somatically acquired mutations. This 
group is initially associated to the intermediate group of the three cytogenetic classification 
groups, if no prognosis-relevant mutations are present. (13) The three most important somatic 
mutations, to date, with high prevalence in AML patients are Nucleophosmin 1(NPM1), 
CCAAT/enhancer-binding protein alpha (CEBPA), and FMS-like tyrosine kinase 3 (FLT3). 
(13) Mutated NPM1, when detected with wild type FLT3, and double CEBPA mutations 
involving N- plus C- terminal alterations, confer a favorable prognosis, whereas FLT3- 
internal tandem duplication (ITD) are associated with adverse outcome. (23) However, the 
relationship of genetic mutations with others, play a major role in leukemogenesis and their 
pathogenetic role. (24) 
1.3 Epigenetic and proteomic deregulation in AML 
1.3.1 Histone Acetylation  
Epigenetic changes refer to alterations in the encoded heritable information by interplay of 
DNA and histone tail modifications. This enables a change of phenotype but does not involve 
a change in nucleotide sequence of the DNA. Consequently, epigenetic alterations are not 
mutations. (25) Acetylation, methylation, and phosphorylation on specific amino acids 
presented on N-terminal tails of the histone proteins, are the mostly studied epigenetic 
modulations besides ADP-ribosylation, ubiquitination, and SUMOylation. (26) Different 
epigenetic modulations occur during normal development leading to a more open chromatin 
configuration (euchromatin) making it more accessible for transcription, or compacting the 
chromatin (heterochromatin) restricting gene transcription. (27) 
 
Most relevant for this thesis is epigenetic regulation by reversible histone acetylation 
performed by valproic acid. (3, 28) Histone acetyltransferases (HATs) catalyze the acetylation 
of lysine residues on the histone tails which opens up the chromatin and allows the 
transcription of genes involved in e.g. cell differentiation, growth arrest and apoptosis, while 
histone deacetylases (HDACs) repress the transcription of those genes by condensing the 
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chromatin through the removal of the acetyl groups. (26, 27) Mutated forms of both HATs 
and HDACs are generally rare within cancers but HDACs are shown to be overexpressed in 
leukemia. (29, 30) The HDACs are categorized into four main classes, with Class I including 
HDAC 1 to 3 and 8, whilst HDAC 4 to 7, 9 and 10 belong to Class II, Class IV contains 
HDAC 11, and sirtuins SIRT 1 to 7 are placed in Class III. (31) Normal cells are relatively 
resistant to HDAC inhibitors (HDACi) induced cell death compared to cancer cells. (32) VPA 
has not only been reported to inhibit the activity of HDAC Class I and II, but also to affect the 
expression of HDAC 2. Approximately 30 % of the protein expression level was reduced in 
murine F9 teratocarcinoma and human embryonic kidney HEK293T cells after 24 hours to 48 
hours VPA exposure. (32) As HDAC and HAT activities regulate gene transcription, HDACis 
can prevent the aberrant down-regulation of essential genes by HDACs. (32) Thus, VPA 
affect differentiation, cell growth and apoptosis by its inhibition of HDACs. 
 
1.3.2 Protein Regulation by Phosphorylation 
Post-translational changes, by covalently modification of nascent polypeptides, are key 
mechanisms regulating functional diversity of proteins biological activity, protein localization 
within the cell, and their binding specificity. (30) The fraction of phosphorylated proteins is 
estimated to be one third of mammalian proteins, hence reducing the complexity of proteomic 
data and enriching the analysis. (33) There is no one-to-one correlation between the 
abundance of messenger RNA (mRNA) to the protein level in the cell. This is due to post-
transcriptional and post-translational changes corresponding to differential splicing, editing 
and modifications. (34) Thus, the transcription of one gene can result into the translation of 
distinct proteins, and consequently, the transcriptional profiling does not provide a clear 
answer to the biological activity and the functional consequences of these changes alone. (35)   
 
Phosphorylation is often an activating modulation that involves an enzyme-catalyzing 
reaction. (33) There are two ways by which the catalytic activity of an enzyme can be 
controlled; either by reversible interaction with ligands or by a covalent modification, such as 
phosphorylation. (36) Protein kinases drive the catalytic events leading to diverse downstream 
signaling. Investigations of AML patients have suggested that somatic genetic alterations and 
overexpressed enzymatically active proteins are the major factors driving the disease. (37) 
The MAP kinase/ERK kinase (MEK)-extracellular signal-regulated kinase (ERK) kinases are 
for example activated through phosphorylation and have been reported to be constitutively 
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activated in more than 50% of primary AML patients and can have pro-survival function. (38, 
39) Phosphoproteomic analyses of primary AML-patients have also discovered post-
translational modifications that may serve as response parameters prior to therapy. (34) 
 
1.4 Treatment  
1.4.1 Conventional Therapy for Acute Myeloid Leukemia 
The mainstay of treatment for newly diagnosed AML patients includes cytotoxic drugs such 
as the standard therapy based on the cytotoxic antibiotics anthracyclines (usually 
daunorubicine) given the first three days with a seven day continuous intravenous infusion of 
the DNA synthesis blocking antibetabolite arabinosylcytosine (cytarabine). (6, 40) This 
treatment is also known as the conventional 3+7 regimen. (41) It starts with a remission 
induction therapy with the goal of patients to enter complete remission (CR), involving 
normalization of the immature blast cell count to less than 5% blasts in the bone marrow, the 
absence of extramedullary AML, and recovery in neutrophil and platelet counts. (42) 
Approximately 60-80% of AML patients younger than 60 years receiving standard induction 
therapy achieve CR, whereas only 50% of patients with an age above 60 receive CR. (13) 
Following induction therapy, the consolidation treatment intend to eliminate remaining 
leukemic blasts to prevent a possible relapse. Unfortunately, most patients experience relapse 
of the disease and a substantial proportion of patients older than 60 years are not considered 
eligible for intensive treatment. For example, the risk of cardiotoxicity associated with 
daunorubicin is one of the side effects impairing its use in elderly patients. (43) Elderly 
patients are rather given lower doses of cytarabine, acquire less-intensive chemotherapy as 
treatment with idarubicin (induces DNA strand breaks) or mitoxantrone (topoisomerase II 
inhibitor) as substituted for daunorubicin, or are recommended to take part in clinical trials 
with investigational drugs. (10, 44) Hypomethylating agents such as decitabine and 
azacitidine can also be offered to older AML patients. (45) Another consolidation therapy 
used is autologous stem cell transplantation (auto-SCT) where stem cells are collected from 
patient prior to chemotherapy or radiation treatment, removed for leukemic blasts at the 
laboratory, and re-infused following treatment. Auto-SCT is an option for younger patients 
with favorable and intermediate risk cytogenetics. (13) However, elderly AML patients 
tolerate this type of SCT less well than younger adults. (46) Allogeneic SCT (allo-SCT), from 
a human leukocyte antigen (HLA) matched donor, is a more common option in AML patients. 
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Patients of favorable risk AML are no longer suggested for allo-SCT therapy whilst the 
survival benefits for patients with intermediate- and adverse-risk AML, are currently being 
discussed. (47, 48) But finding a healthy HLA-matched sibling is less likely in elderly. Older 
patients rarely benefit from standard myeloablative allo-SCT, which consists of high dose 
chemotherapy with irreversible cytopenia followed by mandatory stem cell support, resulting 
in unacceptable transplant related mortality. (49) However, to reduce the procedure-related 
toxicities observed in elderly, conditioning with myeloablative alkylating agents and 
fluarabine have been introduced giving improved results without negotiating the efficacy of 
the transplant. (50) 
 
1.4.2 Valproic Acid in the Treatment of Elderly Patients 
Therapy designed for older AML patients has not improved in recent years compared with the 
considerable progress made in younger patients (51) and the options available are variations 
of standard therapy , treatment by investigating agents in clinical trials or palliative care. But 
as they cannot receive the standard therapy due to an unacceptable risk of mortality, less 
intensive strategies are coveted.  
Valproic acid is a well-tolerated antiepileptic drug that is competent in inducing apoptosis and 
myeloid differentiation in AML. (52) Studies performed on other low toxic chemotherapy 
combined with VPA, e.g. ATRA, decitabine and 5-azacitidine, report toxicity effects to be 
acceptable in older patients with VPA, and to alter the sensitivity of the agents to AML. (53, 
54) Induction of chemosensitivity is observed when VPA is combined with the cytotoxic 
drugs 6-mercaptopurine (6-MP) and hydroxyurea (HU). (55) HU and 6-MP are already well 
established agents and their combination have shown to stabilize AML in relapsed patients. 
(56-58) 
Nevertheless, complete hematological remission is uncommon and only 20-30% of patients 
respond to VPA by showing disease stabilizing effects. On the other hand VPA affects the 
peripheral blood cells composition by increasing the platelet count. And as thrombocytopenia 
(abnormally low levels of platelets in blood) is a common side effect of chemotherapy, VPAs 
increasing platelet count is encouraging concerning blood transfusion independence. (52) 
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1.4.3 The Molecular Potential and Toxicity of Valproic Acid  
VPA (2-propypentanoic acid) is a branched short-chain fatty acid, naturally produced by the 
plant Valeriana officinalis, and synthesized as an organic solvent by B. S. Burton in 1882. 
(59) It is one of the most widely prescribed antiepileptic drugs, also used in the treatment of 
bipolar disorder, and associated with few side effects. However, VPA is known to be 
teratogenic when used during early pregnancy, restricting its use in pregnant women. (59) It 
selectively targets the HDAC class I and less strongly HDAC class II, through inhibition. (60) 
HDAC Class II are fundamental transcriptional regulators of several developmental and 
differentiation processes (32) whereas HDAC Class I play an important role in proliferation 
and cell survival. (61) As they both repress transcription, VPA has shown to reactivate the 
abnormal repressed proteins that have been shown to be important tumor suppressors, for 
example expression reactivation of E-cadherin, P21
CIP1
. (30) One indirect target of VPA is 
p21
WAF1
/CDKN1A, a cyclin dependent kinase associated with cell cycle arrest in G1/S phase. 
(62) This increase of p21 protein expression does not appear to be dependent on the tumor 
suppressor p53, also known as the guardian of the genome. p21 alters molecular pathways 
which in this case would generally lead to cell cycle arrest and apoptosis.  
Active signaling pathways in AML after a response by VPA treatment was investigated in the 
Brown Norwegian Myeloid Leukemia (BNML) rat model, and the discovery of novel 
resistance pathways of VPA was facilitated by the project supervisor Rakel B. Forthun and 
her colleagues. (3) 
1.5 Phosphoprotein Expression Analysis in Acute Myeloid Leukemia  
1.5.1 HK1 and HPRT1 are regulated by Valproic Acid in the BNML Rat Model 
As described above, VPA is effective in the treatment of a subgroup of AML patients. As the 
capacity of cells to maintain cellular survival networks may determine their fate of survival, 
phosphoprotein expression was investigated in the BNML rat model. The BNML model is a 
syngeneic model of human AML, and exhibits many properties that are common with those of 
human AML patients, including an intact immune system. (63, 64) The BNML rats are highly 
responsive to treatment with VPA and can be used to investigate response mechanisms of this 
drug. To elucidate which networks that might contribute to survival of AML cells after 
exposure to VPA, animals were treated for four weeks, and leukemic cells were harvested 
from the spleens when the rats were at a clinical endpoint. (3, 65) Immobilized metal affinity 
chromatography (IMAC) enrichment was used to purify the phosphoproteome before co-
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detection and quantification through fluorescent labeling by difference gel electrophoresis 
(DIGE) and identified by mass spectrometry. Twenty-one novel phosphoproteins were 
discovered to be modulated by VPA, and the researchers suggested that targeting these 
proteins with small molecular inhibitors in combination with VPA could possibly increase the 
anti-leukemic effect of VPA. Hexokinase 1 (HK1) and hypoxanthine – guanine 
phosphoribosyltransferase 1 (HPRT1) were two of the differentially expressed 
phosphoproteins that were identified in this study. The remaining phosphoproteins will not be 
covered in this thesis. Both phosphoproteins were found to have reduced expression after 
treatment with VPA. HK1 is a direct target of Lonidamine (LND), whereas the signaling 
pathway of HPRT1 may be targeted by Mycophenolate mofetil (MMF). Both proteins and 
drugs will be described further in the next chapters.  
 
1.5.2 Deregulation of Metabolism during Tumorigenesis 
The metabolic effect of HK1 and HPRT1 will not be covered in depth in this thesis, but will 
be briefly described in the following section.  
Tumor cells are known to have a high metabolic state. (66) This is done by increasing the 
energy production through the synthesis of lipids, proteins and nucleotides in a manner 
conducive to proliferation. (67) Most biological energy is normally driven from oxidation of 
reduced metabolites (respiration). Even though there is an adequate presence of oxygen, 
cancer cells tend to shift their energy metabolism from primarily relying on mitochondrial 
oxidative phosphorylation, towards a more ineffective way of producing energy by large 
amounts of lactate, referred to as aerobic glycolysis. (68) This phenomenon is called The 
Warburg effect. (69) Why and how cancer cells use this to their advantage is uncertain, and 
how this can be utilized to an advantage of representing potential targets for therapeutic 
intervention is widely focused on in recent research. (70) The two enzymes investigated in 
this thesis HK1 and HPRT1, are both involved in the processing of two important energy 
sources in cancers; glucose and glutamine. Transformed cells consume large amounts of 
glucose entering the cell by plasma membrane glucose transporter (Glut) and captured by 
hexokinase for the stimulation of downstream reactions of glycolysis. (71) The glycolysis is 
held intracellular of the cytosol and can either proceed via the citric acid cycle under aerobic 
conditions inside the matrix of mitochondria, or under anaerobic conditions to produce 
lactate. (72) Glutamine is known to be a key supplement in the culture medium supporting 
cancer growth and it can be metabolized and drive energy production of the TCA cycle in 
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mitochondria to produce adenosine triphosphate (ATP) in a glucose independent manner and 
function as a precursor for the synthesis of lipids, proteins, and nucleotides. (73) 
 
1.5.3 Hexokinases 
Hexokinases phosphorylate 6-carbon sugars using Mg-ATP as phosphate donor, of which 
glucose is the major hexose for most cells to produce energy via glycolysis. (36) Four 
different isoforms of hexokinases exist in mammalian tissues; HK 1-4. (74) Their distinct 
kinetics distinguished their main tissue specificity. Hence, HK4 is mainly found in the liver 
having low affinity for glucose, whilst HK3 is found in the erythrocytes and is least abundant 
in the body. (75) HK1 is the major isoform found in erythrocytes and in the brain with highest 
affinity for glucose, and together with HK2 the main isozymes in muscle. HK2 has high 
affinity to glucose and has a higher enzymatic activity than the other isozymes. (70, 76) The 
higher activity of HK2 might be explained by the two catalytic sites it consists at the C-
terminal and the N-terminal domain. (74) In contrast only the C-terminal has catalytic activity 
in HK1 and HK3. (75) HK4 is smaller than the other hexokinases and is not inhibited by its 
own product glucose-6-phosphate (glucose-6-P) which HK1-3 are. However, the presence of 
inorganic phosphate antagonizes the inhibition of only HK1 by physiological glucose-6-P. 
(76)  But to facilitate enzymatic activity for catabolism of glucose, HK1 and HK2 need to be 
associated with mitochondria. HK2 is suggested to be subcellular translocated for anabolic 
uses. (77) At mitochondria localization, HK1 and HK2 are associated to the voltage 
dependent anion channel (VDAC) through the N-terminal peptide of both isozymes, 
facilitating a directly interaction of the intra-mitochondrial ATP synthesis to glucose 
metabolism. (66) HK3 lacks this sequence of the N-terminal, thus is not bound to 
mitochondria. (66) This first committed step of glucose metabolism plays a role in generating 
energy by converting glucose to the final product pyruvate and ATP, and metabolic 
intermediates such as lipids and nucleotides, for other pathways.  (66) The binding of HK1 
and HK2 to VDAC reduces the available sites for pro-apoptotic factors such as Bak and Bax, 
thus playing a role in preventing tumor apoptosis. (70) Interestingly, attention has been 
brought to HK1 and HK2 as they have been shown with an elevated activity in cancer cells 
being less predisposed to inhibition by their product glucose 6-phosphate allows. (70, 78) The 
up-regulation of HK2 was reported to protect leukemic cells from cell death by escaping the 
intrinsic apoptosis signaling pathway. However its dissociation from the mitochondria 
resulted in induction of apoptosis in HL60 AML cells. (70, 79) Inhibition of this step by an 
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inhibitor may limit the possibilities of cancer cells to regulate the glycolytic pathway, for 
example by their production of higher amounts of lactate. Phosphofructokinase and pyruvate 
kinase serve as the key regulatory targets of glycolysis, and the selective switch to an isoform 
of the pyruvate kinase, PK-M2, has been suggested to be upregulated in leukemia. (80, 81) 
Thus, targeting a catalyst early in the glycolysis pathway may hinders the build-up of 
downstream effects such as PK-M2, or the flux of metabolic intermediates that could be 
shunted into other biosynthetic pathways to the advantage of cancer cells. (36) This might, in 
turn, shift the energy production from glycolysis to cellular respiration in a mitochondria 
dependent citric acid cycle manner. Combining another drug targeting HK1, that could lead to 
a reverse of the enzyme`s anti-apoptotic effect, together with VPA may increase its sensitivity 
to AML cells having elevated glycolytic activity, thus increasing responsiveness of patients.   
The expression of phosphorylated HK1 was found to be reduced after VPA treatment in 
BNML rats. (3) Since this was discovered in late stage disease animals, further analysis was 
needed to unravel whether the reduction was an anti-leukemic effect by VPA or a resistance 
mechanism to VPA. 
 
1.5.4 HPRT1 
Nucleotide biosynthesis is essential for cancer cells to divide. (82) The nucleotide pool has 
been revealed to be larger and the activity of the anabolic pathway is preferentially high in 
rapid proliferating cells. (5, 83) The purine nucleotides include adenine and 
guanine where their respective nucleotide triphosphates, ATP and GTP, are active in the 
metabolism. The synthesis of nucleotides can arise through de novo synthesis or through the 
salvage pathway in a glutamine-dependent manner. (71) In both pathways inosine 5`- 
monophosphate (IMP) is a branch point between guanine and adenine nucleotides, and it is 
the first fully formed purine nucleotide (Figure. 1). During the salvage pathway, this 
compound derives from the purine base hypoxanthine. Hypoxanthine guanine phosphoribosyl 
transferase (HGPRT) catalyzes this reaction to guanosine monophosphate (GMP). Inosine 
monophosphate dehydrogenase (IMPDH) converts IMP to xathosine monophosphate (XMP), 
which is subsequently catalyzed to GMP by GMP synthetase (GMPS). An alternative way of 
the salvage pathway is the directly conversion of guanine to guanosine monophosphate led by 
HGPRT. (84) The production of IMP in the de novo synthesis pathway uses seven ATPs. (85) 
The de novo pathway, which is essentially identical in all organisms, is an energy-consuming 
pathway which replicating hematopoietic cells are greatly dependent on. (86) The salvage 
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pathway utilizes bases or nucleosides available through enzymatic breakdown of DNA and 
RNA or which become available through diet. (36) HPRT1 encodes the enzyme HGPRT 
which adds an activated ribose-5-phosphate to bases, thereby re-utilizing the free bases by 
creating nucleotides through the salvage pathway, as previously shown by Figure 1. IMPDH 
catalyzes the rate-limiting step within the complex biosynthesis of de novo guanosine 
nucleotides. Studies report an elevated level of IMPDH activity in AML patients and the two 
isoforms of the dehydrogenase (IMPDH1/2) in peripheral blood mononuclear cells (PBMC) 
have also been investigated. (87) Implications of a high expression level of type I mRNA in 
PBMCs and lower expression of the type II mRNA of IMPDH in PBMCs were made. (88) 
The opposite has been reported in leukemic cells where activity of IMPDH type II at both the 
mRNA and protein expression level, were higher than that of lymphocytes. (89)  
Densitometric analysis on Northern blots performed on the expression level of IMPDH in two 
AML patients in the study mentioned above, suggested type II mRNA to be the main isoform 
resulting in an increase of a total IMPDH activity in leukemic cells. (90) Goldstein and co-
workers report the induction of myeloid differentiation in HL60 cells after tiazofurin 
treatment, whose mechanism of action is known to be inhibition of IMPDH. (90) Further 
analysis needs to explore whether cancer cells use the salvage pathway to circumvent a block 
in the de novo purine pathway when exposed to chemotherapeutic agents targeting IMPDH. 
 
Figure 1. Hypothetic drug influence on Purine nucleotide metabolism. Reuse of purine bases 
involves the salvage pathway and the de novo synthesis of purine from ribose – 5 – phosphate 
precursors. The HGPRT signaling pathway inhibitor MPA and VPA may influence the synthesis of 
purine nucleotides through the salvage pathway, and IMPDH 2 converting IMP to XMP in the de novo 
pathway is inhibited by MPA. Hydroxyurea (HU) inhibits ribonucleotide reductase converting purine 
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nucleotides (AMP, GMP) into purine deoxyribonucleotides (dADP, dGDP). Figure was revised from 
(91). 
1.6 Mycophenolate Mofetil as a potential anti-leukemic agent 
Mycophenolate mofetil (MMF) is approved for its use as an immunosuppressant agent in the 
prevention of organ transplant rejection by holding lymphocyte-selective anti-proliferative 
effects. (92) Several different chemical syntheses of the phenolic acid have been explored to 
increase its bioavailability since its initial purification from a Penicillium species grown in 
deteriorated maize in 1893. (93) Gosio et.al. found that the active compound, mycophenolic 
acid (MPA), exerted an antifungal property. Nonetheless, MMF exhibits attributes as a  
reversible and noncompetitive inhibitor of IMPDH controlling the de novo guanosine 
nucleotide pool synthesis. There exists two human isoforms IMPDH1 and IMPDH2 that are 
closely related but encoded from two different genes. (93) Lesch-Nyhan syndrome is 
characterized by a lack of HPRT1 gene, thus are not able to recycle purines through the 
salvage pathway.  However, reports show affected people with this syndrome having 
essentially normal function of T- and B-lymphocytes. (94) This lead to the discovery of 
proliferating lymphocytes being depending on de novo nucleotide synthesis for mitogenic and 
antigenic stimulation. (95) Interestingly, a fivefold of inhibition potential of MPA on type 2 
IMPDH has been reported, which has been found to be the main isoform in leukemic cells. 
(87) Synergistic effect has been reported in CML cell lines, where the combination of MMF 
and imatinib overcome the initial resistance to tyrosine inhibition kinase inhibition (TK1). 
(96) Induction of differentiation of HL60 and K562 leukemic cell lines has been shown after 
treatment with MPA. (97) These observations, among others, make MMF to an interesting 
agent for further investigation of the anti-leukemic effect by targeting the purine biosynthetic 
pathway in AML cells. As explained by Figure 1, the inhibition of IMPDH by MMF involves 
the same purine nucleotide synthesis only downstream of the catalyst HGPRT to where VPA 
has been suggested to provoke an effect. Thus, the remaining alternative to produce GMP 
after IMPDH inhibition is through the alternative enzymatic activity of HGPRT which does 
not involve the conversion of IMP to XMP but a direct conversion of guanosine to GMP. 
Thus the anti-proliferative effect seen of VPA might be potentiated through the combination 
with MMF.  
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1.7 Lonidamine 
The effect the indazole carboxylic acid derivative Lonidamine (LND) as an anti-
spermatogentic agent and on embryotoxicity was already clarified in the early 1980. (98) 
Nevertheless it was soon found to bind to mitochondrial bound hexokinase and inhibit its 
action. (99) Further interpretations based on experiments with the drug suggest its activity to 
be membrane-associated rather than direct on the enzyme itself. (98) LND selectively inhibits 
mitochondrial bound hexokinase and not cytosolic hexokinase, and is suggested to result in a 
distinct effect on glycolysis in normal versus neoplastic cells. LND evokes a decrease in 
oxygen consumption in both cancer and normal cells, but enhances aerobic glycolysis in 
normal cells while it inhibits both aerobic and anaerobic glycolysis in human cancer cells. 
(100) Activation of mitochondrial hexokinases is shown to be regulated by Akt/PKB-
mediated phosphorylation. (101) As already mentioned in previous chapters, activated 
mutations of kinases within ERK signaling pathways are frequent events in tumors and also in 
leukemia. ERK and the signaling protein AKT usually operate to negatively regulate 
apoptosis induction. (102) Previous studies report a suppressed efficacy of LND on leukemic 
cells in vitro which provoked an activation of this defensive pathway. (103) However, 
attenuating this activation potentiated LND. VPA has been reported to increase the expression 
of phosphorylated ERK. (104) If LND and VPA work in tandem, the suppressed drug effect 
by this pathway may be withdrawn.    
 
LND possesses poor clinical efficacy when used alone for its anti-tumor properties, however 
it is suggested to sensitize cells to other drugs when combined with for example DNA-
damaging chemotherapeutics. (105) It might also possess a property to overcome multidrug 
resistance by inhibiting cell recovery from potentially lethal damage. (103, 106) Its clinical 
value and efficacy has been proved in combination treatment in completed phase III trials and 
several studies advanced ovarian cancer, (107) glioblastoma multiforme, (108) metastatic 
breast cancer, (109) and inoperable non-small lung carcinoma. (110) Previous in vitro studies 
on leukemic cell lines have included LND for the investigation of its anti-leukemic effect in 
cooperation with the drugs Etomoxir, Arsenic trioxide (ATO), cisplatin and curcumin. (111, 
112) Etomoxir and LND worked together by inducing apoptosis of HL60 cells whereas 
curcumin seemed to potentiate the toxicity of both LND and ATO by generating reactive 
oxygen species (ROS). (4) 
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2. Aims 
 
The potential of VPA was demonstrated by an increase of survival in the rat leukemia model 
BNML. HK1 and HPRT1 are two proteins found to be up-regulated in AML patients, and 
down-regulated in VPA treated BNML rats. However, since the leukemic cells were 
harvested when the rats were sacrificed at humane endpoint, it is of interest to explore 
whether the proteins were regulated as an anti-leukemic effect or a resistance mechanism to 
VPA by the leukemic cells. In this aspect we wish to use the AML cell lines HL60, MOLM13 
and NB4 to: 
 
1. Explore the effect of HK1 inhibitor LND and HPRT1 signaling pathway inhibitor 
MMF in regulating cell death investigating morphological changes by Hoechst 33342 
and phosphoserine membrane alteration and cell permeability by Annexin-V/PI flow 
cytometry, and metabolic activity by WST-1 assay  
 
2. Investigate the effect of MMF, LND and VPA in activating proteins involved in 
apoptosis (caspase 8 and 9), cell cycle (p21), proliferation (ERK1/2) through Western 
blotting 
 
3. Evaluate whether VPA shows synergistic anti-leukemic effect when combined with 
MMF or LND using the method mentioned in aim 1, or transient knockdown by 
siRNA to HK1 or HPRT1 
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3. Materials and Methods 
 
3.1 Cell culture 
3.1.1 Culturing cells 
The human acute myeloid leukemia (AML) cell lines MOLM-13, HL60 and NB4 are 
convenient in vitro tools for chemotherapeutic and pharmacologic investigation and they may 
provide a good basis for studies aiming to understand the control of e.g. the differentiation in 
AML. (113) The use of AML cell lines in experiments allows for comparison to other studies. 
MOLM-13 carries an internal tandem duplication of the FLT3 gene with a functional TP53 
that resembles the majority of primary AML patients. (114) The genetic aberration provides 
the cell a survival and proliferative advantage. HL60 exhibits a deletion of TP53 gene but 
carries an intact FLT3, whereas NB4 is a human acute promyelocytic leukemia (APL) cell 
line with t(15;17), also carrying a mutated TP53. (115, 116) The three AML cell lines were 
selected to represent the varying genotypes of some patient subgroups found in the 
heterogeneous disease. 
All cell lines were grown in Roswell Park Memorial Institute (RPMI) - 1640 medium (Sigma-
Aldrich, Inc. St. Louis, MO, USA) supplemented with 10% heat inactivated Fetal Bovine 
Serum (FBS), 1% Penicillin /Streptomycin (PS) (Sigma-Aldrich) and 1% L-glutamine (LG) 
(Sigma-Aldrich). The cells were incubated and kept at 37 ºC in a 5% humidified atmosphere 
incubator and split every second day. All three cell lines are spherical in shape and grown 
floating in the culture medium (suspension culture). Personal protective equipment was worn 
when working with cell cultures in a cell culture hood, providing an aseptic work area. The 
cells in suspension were passaged before they had clumped together and reached confluence. 
HL60 tend to form clusters although they have not reached confluence. The cell lines were 
passaged every second day by withdrawing of a portion of cells from the culture flask and 
diluted down to the appropriate seeding density. Prior to this, cells were counted by using the 
Bürker chamber. Ten µL cell suspensions were applied to the chamber (0.1 mm) before 
counting the cells in three subsequent squares. The number of cells was divided by three to 
get the average of cells in million per mL cultivated cell suspension.  
HL60 was maintained between 0.5-1.0×10
6
 cells/mL in a split ratio at 1:5 to 1:6, MOLM13 to 
1:4 to 1:5 at about 0.6-1.5×10
6
 cells/mL, while NB4 cells were maintained between 0.5-
1.0×10
6
 cells/mL and split at 1:4.  
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3.1.2 Cell thawing 
Cryopreserved (10% dimethyl sulfoxide (DMSO, Applichem Panreac, GmbH Darmstadt, 
Germany)) cell aliquots were retrieved from liquid nitrogen storage, thawed until a small bit 
of ice remained in the vial and supplied 800 µL of complete fresh growth media (RPMI 1640, 
20% FBS, 1% PS, 1% LG). After five minutes incubation in at RT, the cell suspension was 
mixed gently by pipetting. The cell suspension was transferred to 15 mL tubes containing 5 
mL complete media and centrifuged at 1200 rpm for 5 minutes at RT, with break. The 
supernatant containing fragmented cells and cryoprotectant was removed before resuspending 
the pellet containing viable cells in 7 mL medium  and transferred to a cell culture flask of 25 
cm
2
. If a large degree of cell debris was observed the following day, the cells were 
centrifuged and resuspended in new complete media.  
  
3.1.3 Cryopreserving cells 
Fresh complete media was added to cell cultures the day before cell aliquots were frozen for 
long time storage. Cells were counted and 5 × 10
6
 cells were harvested by centrifugation at 
1200 rpm for 5 min at RT, with break. Freezing medium was added the pellet (70% complete 
RPMI 1640, 20% FBS, 10% DMSO). Cryovials (Sarstedt, Nümbrecht, Germany) containing 
1 mL of cell suspension were placed in a polystyrene box to decreasing the temperature 
approximately 1 ºC per minute at -80ºC until they have reached the equivalent temperature, 
then transferred to a liquid nitrogen tank (-196ºC). (117) 
3.2 NOD/scidILrgamma mice model  
NOD/scidILrgamma (NSG) mice, double homozygous for the severe combined 
immunodeficiency mice, (118) were bred in the Laboratory Animal Facility Vivarium at the 
University of Bergen accredited by Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) International. The mice were originally provided as a 
gift from Leonard Schults (Jackson Laboratory, USA). Their care and housing were in 
accordance with institutional guidelines. (119) Animals were maintained in specific pathogen-
free conditions by housing in closed, internally ventilated cages (IVC), and by conducting 
work in a clean manner by following the dress code of complete change of clothing, wearing 
mask, gloves, separate shoes and a coat. A Maximum Tolerated Dose (MTD) pilot study was 
performed on three female NSG, 8 weeks old, mice by giving 25 mg/kg, and 50 mg/kg 
Lonidamine (LND, AbMole Bio Science, CAS No.: 50264-69-2) dissolved in 70% 
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Poly(ethylene glycol) (PEG300) (Sigma Aldrich), 20% ddH2O and 10% DMSO, resulting in 
reproducible injection of the compound. Intraperitoneal injection (i.p.) was used to administer 
the drug once a day. Two male NSG mice, 18 weeks old, received the drug vehicle only (70% 
PEG300, 20% ddH2O, 10% DMSO). Doses were selected based on previous performed in 
vivo studies and duration of dosing depended on parameters such as clinical signs, weight loss 
and food consumption. (120) The pilot study was designed to minimize the number of animals 
by injecting NaCl subcutaneous over the shoulders, into the loose skin over the neck, to 
recover from treatment if necessary by signs of dehydration and weight loss. 
3.3 Drugs 
Lonidamine (Sigma Aldrich, lot# 043M4038V, and CAYMAN Chemical company, item: 
14640), Lonidamine (AbMole BioScience, CAS No.: 50264-69-2) and 6-Mercaptopurine 
monohydrate (Aldrich Chemistry, CAS: 6112-76-1) were dissolved in DMSO, at 100 mM and 
stored at -20 ºC. Mycophenolate mofetil (CellCept) (90 mM) was dissolved in DMSO and 
stored at -80ºC. Hydroxyurea (Sigma Aldrich, H8527) was solved in 1xphosphate buffered 
saline (PBS). Sodium valproate (DESTIN Pharma, item: 04 69 87, Germany) obtained as 
injection fluid was stored at 4 ºC. All drugs were freshly prepared from stock solutions for 
each experiment. For experiments on drugs when DMSO was used as solvent in in vitro 
studies, concentrations of less than 1% (v/v) DMSO have been shown to not interfere with the 
results. (121) The negative controls in this thesis did not exceed 0.5% DMSO.  
3.4 Cell proliferation assay 
Spectrophotometric quantification of cell proliferation was assayed by the water soluble 
tetrazolium salt-1 (WST-1) (Roche Ltd, Basel, Switzerland) based colorimetric assay. This 
tetrazolium salt is reduced extracellularly to formazan dye by enzymes of the plasma 
membrane oxidoreductase. (122) The primary reductant is NADH derived from the TCA of 
the mitochondria. Hence, WST-1 is converted by metabolically active cells and was employed 
to measure cell proliferation. The cell lines HL60, MOLM13 and NB4 were plated in 
triplicate (20×10
3
 cells/well) in a 96-well microplate and treated with either LND (1, 5, 20, 
50, 100, 200, and 500 µM) or MMF (0.01, 0.25, 0.5, 1.0, and 2.5 µM) or in combinations with 
Valproic acid (0.05 mM – 2.5 mM), Hydroxyurea (2, 10, 40, 100, and 200 µM), 6-
Mercaptopurine monohydrate (1, 5, 20, 50, and 100 µM) in fixed ratios, to a final volume of 
100 µL/well. The negative control contained 90 µL cell suspension and DMSO (vehicle) 
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(v/v%). Following the drug exposure and cell incubation at 37ºC and 5% CO2, Cell 
Proliferation Reagent WST-1was applied to all wells with a final dilution of 1:10 two hours 
prior to examination of the cells after 24 hours or 48 hours treatment. The absorbance was 
measured at a wavelength of 450 nm, with a reference wavelength of 620 nm using the 
Spectramac Plus 348 Spectrophotometer (Molecular Devices Corp., Sunnvale, CA, USA). 
Background absorbance was removed by subtracting values obtained from wells containing 
no cells. The spectrophotometer automatically subtracted the absorbance measured of the 
reference wavelength from that measured from the current wavelength. The value obtained 
from the blank (complete medium only) was subtracted manually from all wells before they 
were normalized to the negative control prior to calculating the percentage metabolism in 
each well, followed by this formula:      
 
    (
𝐴𝑟𝑏𝑖𝑡𝑟𝑎𝑟𝑦 𝑢𝑛𝑖𝑡𝑠 (𝐴𝑈)𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑈 𝑜𝑓 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
) 𝑥 100  
 
Native human AML patient blasts derived from the peripheral blood were separated by 
density gradient (1.077 g/mL, widely used) at the laboratory resulting in AML blast 
population purity of higher than 95%. (113) Two different patient samples were obtained at 
the time of diagnosis. One consisted of peripheral blood sample only whilst both bone marrow 
and peripheral blood samples were provided from the second AML patient. As defined by 
WHO, at least 20% of the bone marrow or blood of AML patients is required to include 
leukemic blasts. The high blast count in the peripheral blood is only seen in subgroups of 
patients. (113) The patient samples were diluted in Iscove`s Modified Dulbecco`s Media 
(IMDM) containing 20% heat inactivated FBS, 1% LG and 1% PS, counted and plated in 
triplicate (1×10
6
 cells/mL) in a 96-well microplate and treated with LND (5, 10, 20, 50, and 
100 µM) alone and in combination with VPA (0.05, 0.1, 0.2, 0.5, and 1 mM), and with MMF 
(0.1, 0.25,0.5, 1, and 2.5 µM) alone and in combination with VPA (0.1, 0.25, 0.5, 1, and 2.5 
µM) to a final volume of 100 µL/well. WST-1 was added to all wells (1:10 final dilution) two 
hours prior to spectrophotometric analysis of the cells after 48 hours treatment, examined 
similar to the cell lines above.   
Cryopreserved (10% DMSO) PBMCs were resuspended in IMDM supplemented with 20% 
FBS, 1% LG and 1% PS, counted and diluted into 1×10
6
 cells/mL and incubated for 1 hour at 
37 ºC in a 5% humidified atmosphere incubator prior to further experiments. Single-drug 
treatment by 48 hours consisted of LND (5, 10, 20, 50, 100, 200, and 500 µM) and MMF (0.1, 
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0.25, 0.5, 1, and 2.5 µM) to a final volume of 100 µL/well. Two hours prior to examination by 
spectrophotometer, the reagent WST-1 was applied in a final dilution of 1:10.  
3.5 Cell viability assay  
3.5.1 Nuclear morphology assay 
The nucleic acid staining reagent Hoechst was used to construct a visible parameter for the 
discrimination of normal from abnormal nuclei. The cell fixation and staining solution 
contained 8% Formaldehyde (Merck-Chemicals KGaA, Darmstadt, Germany) diluted in 
sterile phosphate buffered saline (PBS), and Hoechst 33342 DNA stain (20 µg/mL) 
(Calbiochem, Merck KGaA, Darmstadt, Germany). Immediately after measurement of 
proliferation as described above, Hoechst dye solution was added to the 96-well plates in a 
ratio of 1:1 (v/v) and incubated for 1 hour (4 ºC) prior to analysis of nuclear morphology 
using a Leica DM IRB fluorescence microscope. Cells were scored as normal or abnormal 
where abnormal nuclear morphology was defined as fragmented nucleus and hyper condensed 
chromatin morphological changes characteristic for apoptosis. (123) Cells without these 
characters were scored as normal. For each well, approximately 300 cells were counted to 
calculate the percentage of normal versus abnormal nuclei at each treatment dose. Nucleus 
staining images were obtained using DAPI filter. Percentage of normal nucleated cells were 
normalized to negative control containing cells added vehicle (0.025 % DMSO) and plotted against 
concentrations into a grouped graph using GraphPad Prism 6.0.  
 
3.5.2 Annexin-V/PI Flow cytometry- Phosphatidylserine exposure 
A surface change common by many apoptotic cells is a naturally flip of phosphatidylserines 
(PS) from facing the cytosolic side of the cell membrane to being exposed on the outer leaflet 
of the plasma membrane. (124) This is one of the earliest indicators of apoptosis which can be 
studied by Annexin V`s high affinity for this negatively charged phospholipid. Annexin V is 
not membrane permeable and can therefore be utilized by flow cytometric analysis to 
recognize apoptotic cells when conjugated to a fluorochrome. (125) Cells were plated at a 
density of 0.2×10
6
 cells/well in a 24-well plate and treated with LND (1, 5, 20, 50, 100, and 
500 µM), VPA (0.05, 0.1, 0.2, 0.5, and 1 mM) alone and in combination, or with MMF (0.1, 
0.25, 0.5, 1.0, and 2.5 µM), VPA (0.1, 0.25, 0.5, 1.0, and 2.5 mM) alone and in combination, 
to a final volume of 1 mL in each well for 48 hours at 37 ºC and 5% CO2. Hundred microliter 
of cell suspension from each sample was stained with Hoechst and put aside as an additional 
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control of viability. A volume according to 200 000 cells was transferred to a flow tube and 
washed with 1 mL 0.9% ice-cold NaCl and pelleted through centrifugation at 1000 rpm, 5 
minutes, RT. Each sample was resuspended in 50 µl 1x Annexin V Binding Buffer (BB) 
(Invitrogen, Carlsbard, CA, USA) and 2 µL fluorescent Alexa Fluor® 647-conjugated 
Annexin V (catalog number: A23204, Molecular Probe, Thermo Fisher Scientific Brand). 
Five thousand cell events were collected for each sample on the Guava EasyCyte Flow 
Cytometer containing a dual laser (blue 488 nm, red 640 nm) configuration (6-2L & 6HT-2L 
System Optical Layout). Samples were kept on ice for approximately 15 minutes before 200 
µL 1xAnnexin V BB/propidium iodine (PI) was added to ~ 100 000 cells prior to analysis. 
Late apoptotic and necrotic cells are permeable to PI whilst viable cells exclude this vital dye. 
(125) Visible light emitted by Alexa647/Annexin V was captured by the Red2 Fluorescence 
channel (bandpass filter (661/19)), and PI by the yellow channel (bandpass filter (583/26)). A 
negative control was included containing both fluorophores and cells in the absence of the 
inducing agent (LND, VPA, MMF) and positive controls containing the highest 
concentrations of drug resulting in a suspected positive value of cell death (500 µM LND, or 
7.5 µM MMF).  
3.6 Phosphoprotein purification from Cultured Cells 
Affinity chromatography was used to separate phosphorylated from non-phosphorylated 
cellular proteins. The phosphate groups on amino acids carried by proteins were specifically 
retained on the resin within the columns, whereas proteins lacking phosphate groups were 
discarded in the flow-through fraction. This in situ phosphorylation procedure was based on 
the manufacturer` s instruction (QIAGEN). (126) All reagents used were provided by the 
manufacturer (QIAGEN GmbH, Hilden, Germany, cat. No.37101).  HL60, MOLM13 and 
NB4 cell suspensions of 10
7
 cells in 20 mL complete medium per cell culture flask (75 cm
2
) 
were treated with 1 mM Valproic Acid and incubated for 48 hours in a 37 ºC humid CO2 
incubator. Ten million cells were harvested by centrifugation, 1500 rpm, 6 min, 4 ºC and 
lysed in 5 ml of Phosphoprotein Lysis Buffer (25 mM 2-Morpholino-ethanesulfonic acid 
monohydrate (MES), 1 M NaCl, 0.25% [w/v] CHAPS, pH 6.0) containing one protease 
inhibitor tablet and 10 µL Benzonase® Nuclease (DNase/RNase, > 99% purity) vortexed 
briefly every 10 minutes for 30 minutes at 4ºC. (126) The protein supernatant was harvested 
after centrifugation (13 000 rpm, 4ºC 30 minutes) and concentration was determined by the 
Bradford method as previously described.  Two point five mg of total protein was adjusted to 
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0.1 mg/mL with the Phosphoprotein Lysis Buffer and added to the separation columns after 
equilibration of the columns. To generate a flow rate of approximately 0.5 mL/min for 
optimal binding, half of the lysate was poured into the column and allowed to enter the gel 
bed of the column before applying the second half of the lysate. Columns were washed once 
with PhosphoProtein Lysis Buffer (0.25% CHAPS) before collecting the phosphorylated 
proteins using the PhosphoProtein Elution Buffer (50 mM Potassium phosphate, 50 mM 
NaCl, pH 7.5, 0.25% CHAPS). The protein fractions were concentrated by applying 500 µL 
of phosphorylated protein eluates into NanoSep Ultrafiltration Columns, centrifuged for 10 
min., 13 000 rpm, and combined into one column prior to protein concentration 
determination. Samples were stored at -80 ºC.   
3.7 Isolation and quantification of cellular proteins  
The cell lines HL60, MOLM13 and NB4 were counted and diluted into cell culture flasks 
(10×10
6
 cells per flask), treated with 100 µM LND, 1 mM VPA, and in combination for 48 
hours and incubated at 37ºC with 5% CO2. Cells were centrifuged at 1500 rpm for 6 minutes, 
4 ºC. The pellet was washed three times in ice cold 0.9% NaCl before lysing the cell pellet in 
SHIEH Lysis Buffer (10mM Tris pH 7.5, 1 mM EDTA, 400 mM dithiothreitol (DTT), 
Complete Mini Protease Inhibitor Cocktail (Boeringer Mannheim), and Phosphatase Inhibitor 
Cocktail tablet).  The cell lysate samples were homogenized by gentle pipetting and kept on 
ice for 30 min before centrifugation for 30 minutes at 13 000 rpm, 4ºC. The supernatant, 
containing cell lysate, was harvested and stored in -80ºC until use.  
Protein concentrations were determined using the Bradford method. (127) In brief, six 
different standard samples containing Quick Start Bradford 1x Dye Reagent (Bio-Rad 
Laboratories, Inc. US) and Bovine serum albumin (BSA) (Roche Diagnostic GmbH, 
Mannheim, Germany) in a linear range of 0-10 µg/mL were constructed. Protein samples to 
be analyzed were diluted 1:1000 with Bradford solution, before samples and standards were 
investigated at 595 nm using a microplate reader. The protein solutions were assayed in 
triplicates and normalized to the blank sample containing dye reagent only. A standard curve 
was created by plotting the absorbance of the standard samples on the y-axis, against the 
standard concentrations on the x-axis, obtaining a point-to point relationship for this set of 
standards. A best-fit linear regression line of the entire standard points resulted in an equation 
formatted as following:  
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𝑌 = 𝑎x2 + 𝑏𝑥 + 𝑐, where solving for x was used for interpolating the test sample 
concentrations. The linear regression (R
2
) coefficient indicated how well the obtained data 
fitted to the line. 
3.8 Antibodies 
3.8.1 Primary antibodies 
Rabbit polyclonal antibody to GAPDH 100 µg (1mg/mL, cat. no. ab9585) and Rb pAb to 
coxIV (1mg/mL, cat. no. ab16056) provided by Abcam were used as loading controls for 
western blotting. Other antibodies for target proteins used were rabbit polyclonal IgG 
antibody to caspase-8 p20 (H-134, cat. no. sc-7890), rabbit polyclonal antibody to caspase-9 
p10 (cat. no. sc-7885), rabbit polyclonal anti-pERK (Thr202/Tyr204) (Lot # G2513) and 
mouse polyclonal antibody ß-actin (C4, cat. no. sc-47778). These primary antibodies were all 
ordered from the supplier Santa Cruz Biotechnology whereas the mouse mAb to p21 ([EA 
10], ab16767) was provided by Abcam®, and monoclonal Anti-p21/WAF1/Cip1 (clone P74) 
was gotten from EMD Millipore. The mouse monoclonal Anti-HK2 antibody (SAB5300278) 
was ordered from SIGMA-Aldrich Life Science. 
 
3.8.2 Secondary antibodies 
Rabbit anti-HRP Ab and Peroxidase-conjugated AffiniPure Donkey Anti-Mouse IgG (H+L, 
code: 715-035-150) were provided from Jackson ImmunoResearch Laboratories, inc. 
3.9 SDS-polyacrylamide gels 
The following reagents were used for the SDS - polyacrylamide gel electrophoresis (SDS-
PAGE) gels to yield an acrylamide concentration of about 10%. For one running gel a total 
volume of 5.0125 mL was made containing 1.67 mL 30% Acrylamide/Bis Solution (Bio-Rad 
Laboratories Inc, China), 2.83 mL ddH2O, 0.5 mL 10X TGS 10 µL 10% ammonium 
persulfate (Bio-Rad, catalog number 161-0700) and 2.5 µL TEMED (BIO-RAD laboratories 
Inc, US). One stacking gel was prepared with 1.53 mL ddH2O, 325 µL 30% acrylamide, 625 
µL 0.5M Tris-HCL pH 6.8, 25 µL 10% SDS, 12.5 µL APS and 2.5 µL TEMED. 
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3.10 Western blotting  
All buffers mentioned below were prepared for western blotting and were commercially 
supplied by Bio-Rad Laboratories GmbH or Sigma-Aldrich if not else annotated. Sodium 
dodecyl sulphate (SDS) polyacrylamide gels were prepared in-house to an approximate 
concentration of 10% acrylamide (see section for SDS-polyacrylamide above). Cellular 
lysates of 40 µg or 30 µg per sample were diluted in Loading buffer (final concentration of 
1% SDS, 10% Glycerol, 12 mM Tris-HCl pH 6.8, 50 mM DTT, and 0.1% Bromophenol Blue 
[v/v]) to a total volume of 30 µL. Samples were denatured at approximately 99 ºC for 5 
minutes, placed on ice to cool down samples and spun down briefly prior to loading onto the 
gels alongside a pre-stained standard (Precision Plus Protein ™ Standards All Blue, Bio-Rad 
Laboratories, Catalog # 161-0373, Hercules, Ca, USA), permitting protein molecular weight 
estimation.  
Proteins were separated by size by SDS-PAGE  using SDS-polyacrylamide gels and 1xTGS 
running buffer (10xTris/Glycine/SDS (TGS) containing 25 mM Tris-base, 192 mM Glycine, 
0.1% (w/v) SDS, pH 8.3 diluted in dH2O) at 150 V for approximate 1 hour. Electroblotting 
was performed using Polyvinylidene fluoride (PVDF) membrane (Bio-Rad Laboratories, Inc. 
US) and transfer buffer (10% methanol, (Sigma-Aldrich), 80% dH2O, 10% 10xTris/Glycine 
Buffer[TG, 25 mM Tris, 192 mM Glycine, pH of 8.2]) over night (4 ºC) or at room 
temperature (RT) for 90 minutes, 100 V. After blocking for prevention of nonspecific protein 
binding for 1 hour with 1x TBS, 1% Tween®20 (SIGMA-Aldrich, France) (TBST) and 5% 
Bovine Serum Albumin FractionV (BSA) (Roche, GmbH Mannheim, Germany), the 
membranes were rinsed three times ten minutes with washing buffer, 1X TBST. Thereafter 
the membranes were incubated with primary antibodies  (1:1000) to pERK, p21, caspase 8, 
HK1, HK2, diluted in 1X TBS, 1% Tween®20, 5% BSA overnight at 4ºC. Gapdh and cox IV 
served as internal loading control for equal loading of protein content. They serve as loading 
controls as they are constitutively expressed in all cells and suggested not to be affected by 
the drugs which have been explored in this thesis. Membranes were washed as described 
above to remove unbound primary antibody, prior to incubation with horseradish peroxidase 
(HRP)-conjugated rabbit antirabbit or antimouse antibodies (1:1000, Jackson 
ImmunoReasearch Laboratories, West Grove, PA, USA), diluted in washing buffer containing 
5% BSA, for 1 hour at RT. The membranes were then rinsed thrice in washing buffer prior to 
detection. Antibody detection of the target protein was accomplished by exposing the protein 
bound HRP labeled antibody to a solution of chemoluminiscent substrates 
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(chemoluminescence detection kit: SuperSignal®West Pico/Femto Stable peroxide solution, 
Thermo Scientific, U.S. [1:1]). Protein bands were visualized by light emission captured by 
the Luminescent Image analyzer (ImageQuant LAS 4000, GE Healthcare, Denmark). A 
relative comparison of protein level was quantified using the ImageQuant TL Analysis 
program. In short, the background noise was subtracted prior to detection of bands by the 
software. The volume of material in the band at the detected position (Rf = relative migration 
distance) was quantitated.  The data were then exported to Excel spreadsheet and fold change 
was calculated by dividing the value from the volume of protein of interest by the value of 
volume of loading control. The value obtained was then normalized to the loading control 
(gapdh, coxIV).  
3.11 siRNA   
HL60 cells were cultured as previously described. The siRNA duplexes were designed to 
target the regions of HPRT1 mRNA and HK1 mRNA and were synthesized by Qiagen 
Research, Inc. Hilden, Germany. The transfection of siRNA was performed by following the 
suppliers’ instruction (Invitrogen) using the Neon™ device with Neon™ Pipette Station and 
Neon™ Kits (Invitrogen, Carlsbad, CA, USA). The electroporation parameter for HL60 was 
previously optimized to 1325V, width 35 ms with 1puls per electroporation. MOLM13 cells 
were exposed to one puls of 20 ms with 1725 Volt, whilst NB4 cells had 3 pulses with width 
of 10 ms at 1700 Volt. 10 µl of 20 × 10
6
 cells/ml (Resuspension buffer [RB]) were 
electroporated with HK1(FlexiTube, Cat. No. SI00004193, QUIAGEN), HPRT1 siRNA 
(FlexiTube, Cat. No. SI00004193) or negative control (AllStars Negative Control Alexa Fluor 
488 siRNA, Qiagen) (final concentration 600 nM) using the disposable Neon tips as 
electroporation chamber. Cells were transferred to a 96 well plate containing pre-warmed 
RPMI—1640 medium supplemented with 10% FBS and 1% LG without antibiotics, 50 µM 
LND, 0.1 µM MMF or 1 mM VPA was added after 18 hours incubation siRNA only, before 
cells were incubated for an additional 48 hours. WST-1 proliferation assay was used for the 
analysis of metabolically active cells, prior to scoring of abnormal nuclei as described above. 
To evaluate the proliferation effect of the electroporation process itself, untransfected cells 
were compared to cells electroporated without siRNA. The AllStars Negative Control 
AlexaFlour488 siRNA has no homology to any known mammalian gene and was therefore 
used as negative control for siRNA effect, as well as control for siRNA transfection 
efficiency. Furthermore, three different mock transfection controls consisted of cells in RB, 
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whereof two contained either of the drugs used in the experiments. Data were normalized as 
following prior introducing to GraphPad Prism; electroporated samples without knockdown 
were normalized to electroporated sample treated with vehicle only (DMSO), whilst siRNA of 
interest (HPRT1, HK1) introduced samples were normalized to negative siRNA control 
(AF488).  
3.12 Statistical Analysis 
Throughout the thesis, the graphical representations of the in vitro and in vivo data were given 
as the mean ± standard deviation (SD).  
 
The evaluation of drug combination efficacy was based on the Bliss Independence model. The 
actual combination response was compared with the response to be expected.  The expected 
response value was obtained by using the following formula: 
Yab = Ya + Yb – (YaYb),  
where a resemble the fraction of positive effect by drug A, and b the fraction of the positive 
effect of drug B. If the actual response was higher than the expected (Yab) effect of the two 
drugs, the combination was considered to have a synergistic effect. 
 
The IC50 was obtained by using the IC50 Downloaded Prism file from the software GraphPad 
Prism 6.0. A nonlinear regression fitted the normalized data to a dose-response curve of log-
transformed concentrations (inhibitor) vs. response (variable slope) curve. The relative IC50 
was calculated by the antilog of the value obtained by the software. Negative control constrains 
the top plateau (dotted) lines to 100% in experiments resulting in an enhanced effect of metabolic cell 
activity following drug treatment for an optimal IC50.  
 
Statistical correlation coefficient (r) was calculated by using the CORREL Stats function in 
Excel spreadsheet based on the Pearson`s Correlation. This statistical value was used for 
determining how well associated two variables are. The variables in this thesis were 
normalized percentages of metabolically active cells (WST-1) or viable cells (Hoechst 
staining, Annexin-V/PI). The Pearson`s Correlation formula uses the notations:  
𝑟 =
𝑛(∑ 𝑥𝑦) − (∑ 𝑥)(∑ 𝑦)
√[𝑛 ∑ 𝑥2 − (∑ 𝑥)2][𝑛 ∑ 𝑦2 − (∑ 𝑦)2]
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Where x are the sample variables from for example Hoechst viability assay, whilst y represent 
those obtained from Annexin-V/PI.   
 
All statistical interaction testing were made with a Two-way ANOVA test complemented 
with Turkey`s multiple comparison test, whilst comparisons of two variables with minimum 
sample size of 3 were performed using standard two-sided Student`s t-test.  
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4. Results 
4.1 Assessing the Anti-leukemic Effect of Mycophenolate mofetil in 
Combination with Valproic acid 
The survival benefit of the HDACi VPA is only observed for a minority of AML patients (20-
30%). Alternative co-therapeutics has previously been explored by VPA treatment in the in 
vivo BNML-rat model in order to improve the responsiveness among subgroups of AML 
patients. (3) Here they found a reduced expression of phosphorylated HPRT1. This enzyme of 
the purine nucleotide synthesis may be an alternative target sensitized by MMF.  
Selected human AML cell line models representing AML with limited differentiation (HL60, 
MOLM13, NB4; FAB M2, M4/5) and promyelocytic leukemia (NB4; FAB M3) displaying 
comparable genetic profile to a subset of AML patients, were treated with a concentration 
range of MMF (0.025-2.5 µM) for 48 hours, based on previous drug screen. (96) In order to 
assess the suitability of MMF as an anti-leukemic agent, distinct preliminary drug screening 
assays investigating apoptosis and proliferation were performed on cells following drug 
exposure.  
 
4.1.1 The metabolism inhibiting effect of MMF  
The metabolism assessed with WST-1 assay evaluated the rate of proliferation (methodology; 
section 3.4). Figure 2 A-C illustrates the sensitivity of the different cell lines to MMF 
following 48 hours of treatment. The results suggest that MMF possesses a capacity of a dose-
dependent suppression in that the metabolism is turned down, but the number of cells is the 
same.  
 
Drug efficacy varies among patients, which was correspondingly observed in Figure 2 A-C 
for the cell lines treated with MMF. The IC50 (inhibitory concentration) (Figure 2 D-F) 
predicts the sensitivity of the AML cells lines to MMF. The IC50s ranging from 0.048 to 0.307 
µM indicates that MMF is more effective in MOLM13 (0.048 µM) and NB4 (0.103 µM) 
compared to HL60 cells (0.307 µM). Nonetheless, due to higher standard deviations in HL60 
and MOLM13 (not obtainable by GraphPad), the IC50 values for MMF in both cell lines may 
be present in wider range of concentrations presented as the 95% Confidence Interval (CI). 
Vertical dotted lines in Figure 2 D-F define the inhibition interval of MMF, whereof the 
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bottom line represents maximal inhibition of the drug in the particular cell line. The 
percentage of metabolic activity decreases more rapid in NB4 and MOLM13 cells versus 
HL60 when reaching half maximal inhibitory concentration of the slope (Figure 2F), but the 
efficacy of the drug for all three cell lines was to some extent similar when treated with 0.5 
µM and 1 µM MMF and varied more between the cell lines at concentrations lower than 
0.5µM MMF.  
 
Figure 2. Reduced metabolism by MMF in AML cell lines. Oxidoreductase activity was measured 
after MMF treatment for 48 hours by WST-1 conversion in HL60 cells (A) MOLM13 cells (B) and 
NB4 cells (C). Results were normalized to negative control containing cells in culture with vehicle 
(DMSO) only, and are presented as the mean ± SD of two independent experiments. IC50 (vertical 
dotted line) was calculated in HL60 (0.307 µM, CI: 0.160 – 0.589 µM) (D), MOLM13 (0.048 µM, CI: 
not obtainable) (E), and NB4 cells (0.103 µM, CI: 0.080 – 0.130 µM) (F) as described in section 3.12. 
Vertical dotted lines define the inhibition interval of MMF, whereof the bottom line represents 
maximal inhibition of the drug for each cell line. IC50s interval for MOLM13 was constrained by the 
control due to an increased activity of metabolic cells. Pink shaded area in graphs displays 95% 
Confidence Interval (CI) of MMF. 
 
4.1.2 MMF induces apoptosis in AML cell lines 
The percentage of viable cells with normal nuclear morphology was attained by counting 
normal versus abnormal nuclei (nuclear fragmentation, condensation) (Figure 3B) labeled 
with the double-stranded DNA staining fluorescent dye Hoechst 33342. The evaluation of 
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cells with normal nuclear morphology showed that all three cell lines responded comparably 
similar to all concentrations with MMF, except from the two highest concentrations (1.0 µM 
and 2.5 µM) resulting in higher extent of apoptotic cells in NB4 in comparison to HL60 and 
MOLM13. A clear difference was observed in the amount of viable cells in all three cell lines 
when treated with low dose (0.05 µM) versus high dose (1.0 µM) MMF.  
 
Figure 3. Cell viability by DNA fluorescence staining following treatment with MMF (A) 
Percentage of cells with normal nuclear morphology normalized to negative control containing cells 
added vehicle (0.025 % DMSO). Two independent studies (*n=1) is presented. The reduction of 
normal cell morphology in HL60 cells is illustrated in dark blue, MOLM13 in light blue and NB4 in 
turquoise. (B) Fluorescence microscopy visualizing Hoechst 33342 stained dsDNA of HL60, 
MOLM13, and NB4 cells treated with either the low dose 0.05 µM or high dose 1 µM MMF. Scale 
bar (20 µM) shows the degree of magnification of the image. C – Condensed apoptotic nuclei, F – 
fragmented apoptotic nuclei, V – viable cell nuclei.  
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4.1.3 The effect of MMF on proliferation of PBMCs and AML patient blasts   
To investigate the potential adverse toxic effect of MMF to the peripheral immune system 
function, normal peripheral blood mononuclear (PBMC) cells were treated with MMF. 
Results from WST-1 assay showed no decrease in metabolic activity (Figure 4, circles) 
suggesting that the proliferation of normal PBMCs is not affected by MMF when incubated 
for 48 hours with a range of concentrations (0.25 – 2.5 µM). To explore the in vitro effect of 
MMF in AML patient cell, blasts from two patients were treated with MMF under the same 
conditions as the PBMCs (Figure 4, squares and triangles). The metabolic activity of blasts 
from patient 1 is not reduced when treated with MMF for 48 hours, whereas blasts from 
patient 2 are more sensitive to MMF at lower doses (0.1 – 1.0 µM). The de novo AML Patient 
1had a complex karyotype (≥ 3 acquired chromosome aberrations) with wild type FLT3 and 
wild type NPM1. Comparably, HL60 cells also have an intact FLT3 and showed less 
responsiveness to MMF (Figure 2A). Patient 2 AML cells had normal cytogenetics 
(karyotype 46 XY). FLT3 tyrosine kinase domain mutation ratio was shown to be low (0.07) 
with an internal tandem duplication (ITD) in exons 14 and 15. The presence of ITD confers an 
increased risk of relapse and death. (128) A typical 4-bp insertion mutation clustered within 
exon 11 was detected in the NPM1.  
 
Figure 4. Cell proliferation in primary AML patient blasts and PBMCs treated with MMF for 
48 hours. PBMCs were studied in one healthy donor for a wide range of MMF concentrations (0.025 
– 2.5 µM) whilst both AML patient derived samples were treated with five distinct MMF 
concentrations (0.1 – 2.5 µM). 
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4.1.4 No potential benefit from the combination treatment of MMF and VPA   
This section demonstrates the results with particular interest on whether MMF, an inhibitor of 
the adenosine and guanosine nucleotide biosynthesis, work in tandem with the HDAC Class I 
and II inhibitor VPA and if it represents a useful manner of enhancing the efficacy of VPA 
and MMF alone as anti-leukemic agents. (5, 60) The drug screening in the previous sections 
suggests that all three cell lines respond to the pro-apoptotic and anti-proliferative effects of 
MMF (Figure 2 and 3) alone. Figure 5 demonstrates that VPA by itself elicits minor anti-
leukemic effect at concentrations lower than 0.5 mM with various sensitivities to all three cell 
lines. NB4 were more sensitive to VPA at concentrations from 0.5 mM to 2.5 mM when 
analyzed by WST-1 based proliferation- and Annexin-V/PI viability assays (Figure 5A, C). 
The quantity of metabolically active NB4 cells was reduced by 38% after 48 hour exposure to 
0.5 mM VPA, whilst 58% of the treated cells were considered viable. MOLM13 responded to 
0.5 mM VPA by a decrease in 36% metabolically active cells and 93% viable cells, whereas 
HL60 showed a lower degree of sensitivity to concentrations higher than 0.25 mM VPA in 
both viability and proliferation compared to NB4 and MOLM13. Figure 5 Illustrates the 
capacity of MMF (0.1-2.5 µM) and VPA (0.1-2.5 mM), used alone and in combination to 
reduce the quantity of metabolically active cells and to decrease the viability by inducing 
apoptosis in HL60, MOLM13 and NB4 human AML cells. MMF and VPA cooperated in less 
than additive manner to both reduce the percentage of metabolically active cells (Figure 5A) 
and to decrease the presence of viable cells (Figure 5B, C). Flow cytometric analysis 
confirmed data obtained from microscopy evaluation of apoptosis (Figure 5B). Acquired data 
from Annexin-V/PI apoptosis detection assay showed larger viable population of MOLM13 
cells obtained by co-treatment of VPA (0.25 mM – 1 mM) and MMF (0.25 µM – 1 µM) in 
contrast to when cells were treated with one drug only (Figure 5C). This was also observed 
for NB4 cells at the two highest combination treatment concentrations (1 µM, 2.5 µM MMF, 
1 mM, 2.5 mM VPA). The ability of co-treatment-provoked apoptosis in HL60 cells was 
analyzed by Hoechst 33342 viability assay (Figure 5B), showing no substantial decrease in 
viable cells compared to what is obtained by MMF single drug treatment (Figure 5A). There 
was no significance in the combined effect of MMF and VPA in all three cell lines evaluated 
both proliferation and apoptosis (Hoechst 33342) when tested for Two-way ANOVA 
Turkey`s multiple comparison test and Bliss Independence model (section 3.12) did not 
indicate synergism for the combined treatments with MMF and VPA in all three cell lines 
evaluated by both proliferation and apoptosis (Hoechst 33342). The absence of synergism is 
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exemplified using MOLM13 cells (0.5 µM MMF, 0.5 mM VPA) in Figure 6 where the 
expected amount of metabolically active and viable cells behind was not accomplished.
 
Figure 5. Effect of single-drug treatment and combination treatment of MMF and VPA on 
proliferation and viability of human AML cell lines. (A) Metabolically active cells in HL60, 
MOLM13, and NB4 cells obtained by WST-1 proliferation based assay following 48 hour treatment of 
MMF, VPA, and in combination with concentrations in fixed ratio. Results are given as mean ± SD 
from two independent studies for each cell line. (B) Cell viability detected by Hoechst 33342 and 
analyzed in a single study for HL60, MOLM13 and NB4 cells. (C) Annexin-V/PI flow cytometry 
analysis confirmed the sensitivity for MMF, VPA and combination treatment. The percentage of 
viability of control in three (MOLM13)/ two (NB4) independent studies is presented with mean ± SD 
from MOLM13 and NB4 cells. 5000 events were measured for each concentration. 
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Figure 6. Testing for synergism with Bliss Independence Model for the effect of the 
combinational treatment of MMF (0.5 µM) and VPA (0.5 mM) on MOLM13 cells. Graph 
exemplifies the absence of synergism which was calculated for all three cells lines (not shown). 
Expected fractional response of metabolically active cells versus actual response of co-treatment is 
presented with means ± SD of two independent studies, obtained from WST-1 proliferation based 
assay. Expected versus actual response of apoptosis induction was analyzed by Hoechst 33342 by the 
discrimination of normal and abnormal nuclear morphology.  
 
4.1.5 The Investigation of MMF in Additional Drug Combinations 
All three human AML cell lines in this project showed responsiveness to MMF. Nonetheless, 
MMF did not enhance the anti-leukemic effect of VPA that in particular was the main interest 
with the use of MMF. However, the preliminary results obtained with MMF lead to the 
interest to investigate its attribute in a cooperative manner with other agents. The combined 
treatment of MMF with the well-established agent Hydroxyurea (HU) was further 
investigated. Interestingly, both drugs interfere with the nucleotide synthesis. MMF interferes 
with the conversions from precursors to GMP and AMP, while HU affects up-streams of 
MMF by the conversion of ribonucleotides to deoxyribonucleotides. (56) The combined effect 
of HU and MMF, shown in Figure 7A, followed the same anti-proliferative response to that 
of MMF alone and no additive effect or synergism was achieved. As both HK1 and HPRT1 
were down-regulated by VPA in BNML rats, the combination of LND and MMF (Figure 7B) 
was investigated for potential synergistic or additive effect on proliferation and apoptosis. (3) 
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This combination neither showed significant enhanced potentiation of MMF nor LND. 
 
Figure 7. Combination treatments exploring the potential utility of MMF as a cooperative drug 
with other agents. WST-1 proliferation based assay was applied for the pilot experiments; (A) MMF 
with literature based concentrations of HU (129), in two independent treatment studies of MOLM13 
cells for 48 hours, and (B) one study of MMF combined with LND in NB4 cells (48 h).  
 
4.1.6 Transient suppression with unmodified HPRT1 siRNA changed the effect by VPA 
treated HL60 cells  
Promising synergistic effects were not obtained in vitro from the combination treatment of 
MMF and VPA on HL60, MOM13 and NB4 cells. Thus, knockdown of HPRT1 was 
performed to elucidate whether a more specific direct targeting of the enzyme can increase the 
anti-leukemic effect of VPA. HL60 was found to be the least sensitive cell line to MMF at 
lower concentrations, where 0.1 µM resulted in approximately 70% metabolically active cells.  
In order to investigate the influence of MMF on HPRT1-signaling in HL60 cells, HPRT1 
siRNA was directly introduced into HL60 cells by electroporation using Neon Transfection 
system allowing knockdown of HPRT1. For the establishment of a balance between cell 
viability after transfection and delivery efficiency, optimized variables for each 
electroporation of HL60 cells were previously determined. The change in proliferation by 
HPRT1 knockdown was examined by WST-1 conversion (Figure 8). The electroporation 
procedure was observed to be tolerated by the cells affecting the reduction of only 3% 
metabolically active cells. Scrambled negative siRNA control to AF 488 dye, demonstrated 
the transfection efficiency. Quantification of successfully transfected cells was not obtained 
from this study. Figure 8 shows no difference of the extent of metabolically active cells 
between HPRT1 siRNA transfected and un-transfected cells, treated with vehicle only. This 
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suggest that knockdown of HPRT1 does not result in decreased level of metabolically active 
cells by itself. Treatment with MMF on cells with HPRT1 knockdown did not lead to a 
change in the effect on proliferation from what is obtained with MMF alone. These data 
demonstrate that no further enhanced effect from MMF to reduce proliferation in HL60 cells 
was achieved by knockdown of HPRT1. However, knockdown of HPRT1 in HL60 cells 
measured 48 hours after addition of VPA affected the rate of metabolically active cells. This 
enhanced treatment effect in HL60 cells, compared to from what is obtained by VPA alone, 
suggests for an increased anti-leukemic effect with VPA when combined with a HPRT1 
specific targeting agent. But for the findings of this experiment to be of statistical significance 
and not due to chance, further replicates are needed.   
 
Figure 8. Effect of gene specific knockdown by HPRT1 siRNA in HL60 cells. siRNA (negative 
control AF488 and HPRT1) was introduced to cells by electroporation prior to incubation for 18 hours 
and subsequent treatment with MMF (0.1 µM) or VPA (1 mM) for additional 48 hours in two 
technical replicates of one experiment. The metabolism inhibiting effect on cells was assessed by the 
WST-1 proliferation assay. HPRT1 knockdown caused no change in effect of MMF on proliferation, 
whilst the potential of VPA to reduce proliferation was improved. Electroporated samples with no 
transfection (-) were normalized to electroporated sample treated with vehicle only (DMSO), whilst 
siRNA (HPRT1) introduced (+) samples were normalized to negative siRNA control (AF488). Means 
± SD are displayed by error bars. 
4.2 Effect of Lonidamine in HL60, MOLM13 and NB4 cell lines in in vitro 
experiments 
Lonidamine (LND) has been reported to elicit poor cytotoxic effect by itself but to augment 
the efficacy of other antineoplastic drugs. (106, 111) Only at concentrations higher than 100 
µM, LND has shown to reduce the viability of cancer cells. The following sections present 
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results that can support the reproducibility of experiments with LND holding properties such 
as anti-tumorigenecity. 
 
4.2.1 Assessing appropriate LND exposure time by Proliferation Assay and IC50   
All three AML cell lines (HL60, MOLM13, NB4) were exposed to increasing concentrations 
of LND (1 – 500 µM) for 24 and 48 hours in a dose range previously described by others in 
various cancer cells, mainly solid tumors. (130) The comparative sensitivity of each cell line 
to LND for 24 hours is presented in Figure 9A. No significant difference (𝑃 >0.05) in 
reduced metabolically active cells was obtained between HL60 and NB4 cells after 24 hour 
treatment with LND. Both cell lines responded by approximately 20% reduced metabolically 
active cells at concentrations lower than 50 µM LND. Higher concentrations (> 100 µM) of 
LND were needed for a significant (𝑃 = 0.0105) decrease in metabolically active MOLM13 
cells. There was no strong evidence that HL60, MOLM13 and NB4 cells responded different 
to treatment with higher concentrations of LND (> 50 µM). IC50s of LND was obtained from 
WST-1 proliferation assay, and are presented in Figure 9B, C and D for HL60 (149 µM), 
MOLM13 (218 µM) and NB4 (203 µM), respectively. A wider 95% CI is observed for the 
IC50 of LND in treated NB4 cells (Figure 9D) than for HL60 and MOLM13, thus we cannot 
exclude the possibility that the IC50 of NB4 could be present anywhere between 106 – 387 
µM. The inadequate PBMC sample size limited statistical evaluation of the difference in 
effect by LND on proliferation in PBMC versus AML cell lines. Nonetheless, Figure 9A 
illustrates that the sensitivity of MOLM13 to LND is not higher than to what is observed for 
the PBMCs when treated for 24 hours.  
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Figure 9. Minor decrease in metabolically active cells following 24 hours treatment with LND. 
(A) HL60, MOLM13, NB4, and PBMC response on metabolic activity following LND exposure. (B) 
HL60 (149 µM, CI: 110-200 µM), (C) MOLM13 (218 µM, CI: 153 – 311 µM), and (D) NB4 (203 
µM, CI: 106 – 387 µM) dose response curves displaying IC50 values (vertical dotted line) between the 
maximal response (top horizontal dotted line) and the maximal inhibited (bottom horizontal dotted 
line) response of the drug. Purple shaded area displays 95% CI of IC50 value.   
 
The efficacy of LND to reduce proliferation in HL60 was similar to when exposed for 24 
hours, whilst NB4 cells responded by an increase in proliferation at concentrations lower than 
100 µM. Increased LND incubation time from 24 hours to 48 hours significantly (𝑃 < 0.05, 
20 µM – 500 µM LND) (𝑃 < 0.0034, 5 µM LND) affected proliferation of MOLM13 cells. 
The distinct response of PBMC comparable to MOLM13 and HL60 is noticeably 
demonstrated in Figure 10A. NB4 was significantly (𝑃 < 0.05) more sensitive to LND under 
24 hours of exposure than 48 hours (5 – 500 µM). The IC50 of LND in NB4 (201 µM), HL60 
(248 µM) and MOLM13 (124 µM) are presented in Figure 10 B, C and D indicating LND to 
be more effective after 48 hour treatment in MOLM13 and NB4 cells at lower concentrations 
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than when treated for 24 hours. The 95% CI for NB4 was very wide and not obtainable by 
GraphPad Prism due to an increase in percentage of metabolically active cells. 
 
 
Figure 10. Reduced cellular oxidoreductase activity following 48 hours treatment with LND. (A) 
PBMC and NB4 cells increased in metabolically active cells at concentrations < 50 µM and 100 µM, 
respectively, whilst MOLM13 and HL60 enhanced sensitivity to LND compared to 24 hour exposure. 
Half maximal inhibitory response (vertical dotted line) was assessed from WST-1 conversion data in 
(B) HL60 (135 µM), (C) MOLM13 (46 µM) and (D) NB4 (182 µM) cells. 95% CI is presented in 
purple shaded area in graph. (NB4 CI was not obtainable) 
 
4.2.2  Apoptosis induction by Lonidamine of human AML cell lines  
LND elicits potential of inducing apoptosis after both 24 hours and 48 hour incubation at 
higher concentrations (> 50 µM) in HL60, MOLM13 and NB4 (Figure 11A-B). Apoptotic 
cells in the stage of morphological changes such as fragmented or condensed nuclei are 
shown in Figure 11C, visualized by fluorescence microscopy. The frequencies of abnormal 
nucleic morphology were minor at concentrations lower than 50 µM in all three cell lines. 
However, the incidence of cells being in an earlier apoptotic stages may be present but not 
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detected under examination. Cells may therefore be likely in a pre-apoptotic phase induced by 
lower concentrations of LND.   
Figure 11. Effect of LND on cell viability in human AML cell lines following exposure of 24 and 
48 hours. Quantification of abnormal nuclei after three independent treatment-studies of LND in 
HL60, MOLM13 and NB5 cells for (A) 24 hours and (B) 48 hours. Error bars are presented as means 
± SD. (C) Nuclei presented in both apoptotic and viable morphology, visualized by Hoechst 33342 
staining and scored as: V – Viable cells, C – condensed apoptotic nuclei morphology, F – fragmented 
apoptotic nuclei. Scale bar: 20 µM. 
 
4.2.3 Dose Dependent Synergistic Effect of Lonidamine and Valproic Acid 
Few studies have investigated the potentiation of LND activity to enhance drug cytotoxicity in 
a dose and schedule dependent manner. (131) Thus sequence administration (Figure 12) and 
optimization of treatment with LND (50 and 100 µM) in combination with VPA (0.5 and 1 
mM) was performed. These are concentrations that showed enhanced potential of anti-
proliferative activity when combined (Figure 13A) in the least sensitive cell line HL60, 
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examined in this project. The concentration of VPA that, by itself, reduced the surviving 
fraction of target AML cells by approximately 10 % (0.5 mM and 1 mM) was chosen. HL60 
cells were exposed to the drugs in two different sequences; LND incubation for 24 hours prior 
to 48 hours combined treatment with VPA and LND (LND  VPA+LND) and the reverse 
(VPA  LND+VPA). This sequenced treatment was compared to a 48 hour combined study, 
without pre-treatment of LND or VPA, to investigate whether LND could enhance the anti-
proliferative effect of VPA against the human AML cell line HL60. The results were 
normalized to the negative control with vehicle only (DMSO [v/v%]) and plotted as a 
logarithmic graph (Figure 12). Maximal potentiation of LND was obtained by 100 µM LND 
in the sequence VPA  LND+VPA, but no significant increased anti-proliferative effect was 
obtained from three independent and replicable studies. These preliminary results are 
supported by previous experiments showing the anti-proliferative effects of VPA to increase 
with increasing exposure time. (132) 
 
Figure 12. Sequence administration on HL60 cell proliferation of VPA (0.5 mM, 1 mM) alone 
and in combination with LND (50 µM, 100 µM). The order of administrations were: 
LNDLND+VPA, VPALND+VPA for a total exposure time of 72 hours compared to LND+VPA 
combined for 48 hours, and VPA alone for 48 and 72 hours. Results are given in means ± SD in 
triplicate. **P < 0.01  
 
To evaluate whether LND works in tandem with VPA, selected concentrations were applied 
to MOLM13, NB4 and HL60 cells for 48 hours based on single drug treatment results 
obtained in section 4.2.1 and previous in vitro studies on VPA (133). Hoechst 33342 assay 
provided viability data by the quantitative counting of abnormal and normal nuclear 
morphology (Figure 13A, HL60 shown only). Annexin-V/PI flow cytometric analysis, 
besides Hoechst 33342 staining (Figure 13A) confirmed apoptosis results. Correlation 
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coefficients were computed to address the association strength between both viability assays. 
The decrease in viability attained from the combination treatment in both assays correlated 
well with each other. The correlation coefficients for the strong association between Hoechst 
33342 – and Annexin-V/PI viability assay in MOLM13 and NB4 were 0.99 and 0.88 
respectively. These data indicated a comparable trend of viability in all three cell lines 
following combinatorial treatment of VPA and LND (Figure 13B, C). HL60 cells are only 
presented for Hoechst viability scoring in figure 13A since the cells do not expose 
phosphatidylserine upon apoptosis induction.  
 
Figure 13. Cytotoxic potentiation by LND (100 µM) when combined with VPA (1 mM) on AML 
cell lines. Viability was analyzed after 48 hour combination treatment using (A) Hoechst 33342 
staining (HL60 shown), and (B) Annexin-V/PI flow cytometry in MOLM13 and NB4 cells. (C) 
Analysis of viable (AnnexinV-PI-), pre-apoptotic (AnnexinV+PI-), and apoptotic (AnnexinV+PI+, 
AnnexinV-PI+) is demonstrated with enhanced amount of apoptotic populations of LND (100 µM), 
VPA (1 mM) co-treatment of NB4 cells. 
 
Anti-proliferative activity following combination treatment with VPA and LND varied among 
the cell lines (Figure 14A-C). An overall higher degree of reduced metabolic activity was 
observed from three independent studies with MOLM13 (Figure 14A) and NB4 (Figure 
14B) cells thus were suggested being more responsive to co-treatment. However, higher 
standard deviations across the concentrations (mainly at VPA concentrations ≤ 0.2 mM), 
contribute to more variance and uncertainty associated with statistical interference of the 
combination treatment. HL60 cells responded revealed low response to both drugs alone, 
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resulting in only 10-25 % reduced proliferation when exposed to the highest concentrations of 
VPA (1 mM) and LND (100 µM), respectively (Figure 14C). Nonetheless, the combined 
treatment with 100 µM LND and 1 mM VPA reduced the level of metabolically active cells to 
47 % in HL60, proposing the evident of a dose-dependent effect. Synergistic induction of 
apoptosis and reduced proliferation for this dose was demonstrated by the Bliss Independence 
Model (Figure 14D) and calculated for statistical significance by Two-way ANOVA 
Turkey`s multiple comparisons test (***P=0.001).  
 
Figure 14. Combinational treatment effect of VPA and LND on cell metabolism and viability of 
human AML cell lines. Sensitivity for treatment with LND and VPA alone and in combination 
(actual response) for 48 hours analyzed by WST-1 shown for MOLM13 (A) NB4 (B) and HL60 cell 
lines (C). All results are given as mean ± SD for three independent experiments. (D) Synergism on 
viability obtained from Hoechst staining and proliferation inferred by metabolically active cells. 
Synergistic effect was calculated by Bliss Independence test (expected response) represented in means 
± SD in three independent studies on HL60 cells with 100 µM LND combined with 1 mM VPA. p-
values calculated by Two-way ANOVA Turkey`s multiple comparisons test (***P = 0.001) 
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Since LND has been reported to sensitize other chemotherapeutics (105), it was investigated 
whether LND could potentiate hydroxyurea (HU) and 6-mercaptopurine (6-MP) that are both 
been used for therapy in AML patients. (56) The proliferative response following treatment 
was examined for both combinations. Interestingly LND, seemed to inhibit the effect of HU 
when combined in HL60 cells (Figure 15A). This was also observed by scoring normal 
versus abnormal nucleated cells (Figure 15B). Combinational treatment of cells with 6-MP 
and LND was investigated by proliferative response were the combined effect did not exceed 
that of either of the drugs alone (Figure 15C). 
 
Figure 15. In vitro evaluation of LND in combination with HU and 6-MP. Bliss Independence test 
examined the expected response of the combination treatments (actual response) from one study on 
HL60 cells (48 h). (A) Both proliferation and viability assays assessed an inhibited response of HU 
when combined with LND. (B) 6-MP and LND showed no synergism when combined.  
 
4.2.4 AML Patient cells treated with Lonidamine and Valproic Acid 
Drug screening of patient blood samples by proliferation assay was performed to determine 
drug response and drug sensitivity with LND (1 – 100 µM), VPA (0.05 – 1 mM) alone and in 
combination treatment for 48 h. AML cells from two AML patients exhibited different degree 
of sensitivity to the treatment of single drug LND (1-100 µM), VPA (0.05-1 mM) and the 
combination treatment in vitro (Figure 16). Peripheral blood samples, enriched for leukemic 
blasts by density gradient separation (Lymphoprep), from patient I (Figure 16A) showed less 
response on proliferation to both drugs compared to patient II (Figure 16B). Treatment of 
blasts derived from patient I resulted in an additive anti-proliferative effect by the 
combination treatment of 50 µM and 0.5 mM. A sample size of one is not substantial for 
significance testing. However, Bliss Independence model allowed for synergy testing. Bliss 
Independence model revealed synergism for the combination treatment of 50 µM LND and 
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0.5 mM VPA on patient I. The expected response in Figure 16 defines the equation (section 
3.12) of the Bliss Independence rule for synergism. Patient II was more responsive to both 
LND and VPA than patient I, resulting in less metabolically active blasts from peripheral 
derived blood after treatment. A bone marrow sample was available for patient II, and was 
treated identically to the blast samples. The cells harvested from the bone marrow showed 
lower response represented by increased proliferation for all combination doses except 100 
µM LND and 1 mM VPA. VPA and the combined treatment followed a similar trend parallel 
to that obtained in peripheral blood sample, only with an overall increase in proliferation with 
lower drug response. LND had an enhanced effect on the bone marrow derived sample 
resulting in 30% less metabolically activity than the peripheral blood sample when treated 
with same concentration (50 µM). However, PBMC sample Figure 10A appeared more 
resistant to LND than the primary AML patients.  
 
Figure 16. Proliferation changes in AML patient leukoblasts and bone marrow samples treated 
with LND and VPA. Synergistic effect was calculated by using the Bliss Independence test model 
(expected response). (A) Additive effect of reduced proliferation from the combination treatment with 
LND and VPA. Synergism indicated when combined with 50 µM LND and 0.5 mM VPA in patient I. 
(B) Sensitivity of peripheral blood sample derived from AML patient II to both agents when treated 
alone and in combination, but no additive or synergistic effect was specified. Bone marrow derived 
sample from same patient show greater sensitivity to LND when treated with 50 µM or 100 µM LND 
alone, or else more resistance to the drugs.  
 
4.2.5 Transient Knockdown of Hexokinase I Potentiating VPA Effect on Proliferation in 
MOLM13 and NB4 human AML cells 
siRNA on HK1 was introduced into HL60, MOLM13 and NB4 cells to investigate if a 
knockdown of this gene affect the sensitivity of the cell lines to LND (50 µM) and VPA (1 
mM) and whether the drugs efficiently inhibit HK1 when present under treatment. The 
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specificity of LND to inhibit HK1 can to some extent be evaluated by examining whether 
HK1 knockdown cells treated with LND result in a less effect of anti-proliferation compared 
to knockdown only. Experiments in HL60 confirmed the LND-dependence of HK1 (Figure 
17A), were HK1 knockdown cells were less sensitive for LND compared to control 
transfected cells. Nonetheless, the HK1 siRNA control cells may have responded to the 
knockdown of HK1 by stimulating proliferation which could be the same response observed 
in cells treated with LND after knockdown (Figure 17A). No significant change in VPA 
response was observed after HK1 knockdown in HL60 cells. HK1 knockdown-mediated VPA 
sensitization may be observed in MOLM13 (Figure 17B), but repeated experiments are 
needed for confirmation. A comparable effect with 80% reduced proliferation was obtained in 
MOLM13 HK1 knockdown control and in MOLM13 cells with HK1 knockdown and VPA 
treatment (Figure 17B). Figure 17C displays the high SDs from the results in NB4 cells. 
Together with the already high sensitivity of NB4 cells to VPA, the SDs problematizes the 
reliability and the actual effect of the knockdown.  Normalized data to the consistent controls 
are presented in Figure 17 A, B and C for HL60, MOLM13 and NB4, respectively. In 
MOLM13 and NB4 (P = 0.037*) cells, knockdown of HK1alone potentiated anti-
proliferation.  
Figure 17. Transient in vitro knockdown of HK1 in HL60, MOLM13 and NB4 AML cells by 
electroporation prior to treatment of LND, VPA or vehicle (DMSO) for 48 hours. The siRNA 
serving as negative control was AF488 labeled. Two replicates of one study in (A) HL60, (B) 
MOLM13 and (C) NB4 cells presents the potential of LND and VPA to reduce cell proliferation in 
non-/ introduced siRNA to HK1. Untransfected samples were normalized to untransfected control, and 
knockdown (HK1 siRNA) samples were normalized to negative siRNA control (AF488 siRNA). (-)  – 
negative for siRNA, (+) – introduced siRNA. 
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4.3 The effect of Lonidamine and Valproic acid on Hexokinase and other 
signaling pathway proteins  
Western blotting was performed in order to reveal specific proteins and signaling pathways 
affected by VPA or LND. Phospho-HK1 was shown to be affected by VPA in a previous 
proteomic study that found reduced protein expression of phosphorylated HK1 in the 
leukemic cells of VPA treated BNML rats. (3) As LND is not specific to HK1, but is 
characterized to be an inhibitor of the activity of mitochondria bound hexokinase, the 
expression level of both HK1 and 2 was investigated. The expression levels of HK2 varied 
marginally between all lysates within the cell lines. No defined up- or down-regulation could 
be confirmed, except from a LND treated samples, having to some extent reduced HK2 
expression (Figure 18). Protein expression of HK1 was shown to increase in all cell lines 
after treatment of VPA and the combination of LND and VPA (Figure 18). But as the 
explored VPA- modulated protein expressions in the BNML-study were phosphorylated, the 
decreased HK1 expression may only represent a fraction of the total HK1 protein expression 
in whole cell lysates as observed in this project. Thus the previously observed effect of VPA 
on HK1 may not be reflected by these western blots. (3) Phosphorylated proteins from 
cultured HL60, MOLM13 and NB4 cells were therefore purified by affinity chromatography 
after treatment with VPA or LND. The concentration of the phosphorylated proteins was 
however not sufficient to permit further evaluation by western blotting.  
  
Figure 18. Normalized quantitated data for the compared protein expression of HK2 and HK1.  
Western detected presence of HK1 and 2 following 48 hour treatment of LND (100 µM), VPA (1 mM) 
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and the combination of both drugs. Gapdh serves as internal loading control for three independent 
studies.  
 
In order to assess the functional pathways of LND and VPA in leukemic cells, four other 
proteins, caspase 9, caspase 8, p21 and pERK1/2 were investigated.  
Caspase 9 is cleaved as a step of the initiation of the intrinsic apoptosis signaling pathway, 
and caspase 8 is cleaved during activation of the extrinsic pathway. These proteins were 
therefore analyzed as a proof of activation of cell death. Figure 19 A shows decreased 
expression of cleaved caspase 9, and a clear accumulation of cleaved caspase 8 in NB4 cells. 
MOLM13 treated cells showed similar caspase expression levels, whilst HL60 cells resulted 
in activation of both apoptosis signaling pathways when treated for 48 hours with 100 µM 
LND, 1 mM VPA and in combination. P21 is a protein downstream of and under the control 
of p53. As p21 regulates cell cycle progression by an arrest at G1/S phase, the expressed level 
of the protein could indicate whether there is a cell accumulation in the G1/S compartment 
following drug exposure.  The increase in protein expression of p21 was seen in all cell lines 
when treated with VPA, with the highest increase in MOLM13 and NB4 (Figure 19B). The 
increase of p21 expression level is supported by previous findings. (134) All cell lines 
exposed to LND had increased p21 protein expression, however it reduced the large increase 
induced by VPA when combining the two drugs. ERK signaling pathway frequently operates 
by negatively regulating apoptosis. Although both VPA and LND have been reported to 
increase the expression of phosphorylated ERK, combination studies on LND have shown a 
reduced expression of pERK when working in synergism with other drugs. (103) pERK1/2 
protein expression was reduced following 100 µM LND treatment and increased after 
exposure to 1 mM VPA. The low expression increase by VPA was counteracted by LND 
when combined (Figure 19C).  
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Figure 19. Expression levels of proteins involved in apoptosis regulation and proliferation 
following LND and VPA treatment. Characterized protein bands were normalized to loading 
controls (gapdh or cox IV). (A) Cleaved form of caspase 9 and caspase 8 present active intrinsic- and 
extrinsic apoptosis signaling pathways in treated NB4 cells. (B) Cell cycle regulatory protein p21 
content assessment by quantitative analysis of its protein expression in NB4 cells following treatment. 
(C) Expression of the ERK signaling pathway by phosphorylated ERK1/2 expression in MOLM13 
cells. 
4.4 Murine MTD study assessing tolerance of selected drug concentrations of 
Lonidamine 
Based on the interesting and encouraging in vitro data, a pilot study to determine maximum 
tolerated dose was performed in NOD/scid/gamma (NSG) mice. Doses were determined 
based on the literature for evaluating the tolerance of LND. (120) Three female mice received 
intra peritoneal (i.p) injections of LND once daily for five days with five day observation. 
Weight was measured every day and the condition of the mice was followed by observation 
(Figure 20). Injections of 25 mg/kg LND once a day for five days (Figure 20A) resulted in 
approximately 7% weight loss in two mice, whilst the third mouse gained weight by ~ 3%. 
Nonetheless, the condition of the mice was normal with no visual signs of change in 
movement and activity. Five minutes after the first injection of 50 mg/kg LND the mice 
responded with apathy. They moved when disturbed, but quickly resettled. After 24 hours, the 
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appearance of ruffled fur, dehydration, little movement with quickly resettling, and average 
weight loss down of 9.61% of total body weight (𝑃 < 0.05), led to the decision of ending the 
trial of 50 mg/kg LND dosing (Figure 20B). Subcutaneous injections of 9 mg/mL sodium 
chloride were administered for one week for recover and weight gain. Because of the high 
loss of body weight, 25 mg/kg LND was considered as the MTD in this study. The two male 
NSG mice receiving vehicle only, resulted in no significant weight loss.  
Figure 20. Maximal tolerated dose evaluation of lonidamine in NOD/scid/gamma (NSG) mice. 
Weight was measured every day and normalized to weight prior treatment, presented as average 
percentage body weight in graph. Syringe indicates day of i.p. injection and the symbols represents 
variation between mice.  (A) 25 mg/ml LND administered once daily for five days in three female 
NSG mice. (B) 50 mg/kg of compound reached above the maximum tolerated dose causing toxicity by 
excessive weight loss close to 10% of body weight. Two male control NSG mice were given vehicle 
only i.p. (10% DMSO, 70% PEG300) for one day.  
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5. Discussion 
 
In vitro preliminary studies based on metabolism- and apoptosis assays on human AML cell 
lines treated with either of the drugs LND or MMF enabled us to investigate whether the 
drugs possess an anti-leukemic potential by themselves and if they enhances that of VPA. 
Because LND is suggested to selectively inactivate mitochondria bound HK1 and HK2 
primarily in tumor cells, one would expect to affect the glycolysis potentially promoting 
downstream apoptotic activity in AML cells when treated with LND. (100, 135, 136) MMF is 
a potent inhibitor of IMPDH that has been demonstrated to be a key enzyme of the de novo 
purine synthesis with higher activity in neoplastic cells. (5, 137) The targeted enzymes HK1 
and IMPDH are both involved in the signaling pathways that were previously observed to be 
affected by VPA. (3) For that reason LND and MMF were chosen as investigating agents in a 
subset of AML in vitro studies. As the discovery of those proteins was based on the isolation 
of leukemic blasts from animals at humane endpoint, further analysis needed to evaluate 
whether their regulation was of an anti-leukemic effect or a response of resistance to VPA. 
Consequently, novel in vitro drug combination strategies for AML were investigated and 
evaluated by anti-proliferative and apoptosis assay. Further investigation of the drugs 
mechanism of action was done by Western blot analysis. Transient knockdown of HK1 and 
HPRT1 was performed to investigate a more direct inhibition of these proteins, and the 
potential combination potential with VPA. Ex vivo proliferation studies enabled the 
postulation of drug sensitivity in subgroups of AML patients to LND and MMF.  
5.1 Assessing Anti-leukemic Potential of Drug Combinations In vitro 
Enhanced enzyme activity of IMPDH has previously been linked to increased proliferation in 
leukemic cells. (87) Given that glutamine is an essential fuel for cancer cell metabolism where 
purine synthesis is dependent on this nutrient and that IMPDH is the rate limiting enzyme of 
the de novo guanosine synthesis, we hypothesized that the potential of the semisynthetic drug 
MMF to inhibit IMPDH may possess an additional anti-leukemic effect when combined with 
VPA. The human AML cell lines HL60, MOLM13 and NB4 selected to represent varying 
subgroups of patients in the heterogeneous disease AML indicated sensitivity by proliferation 
and viability assays to MMF. IC50s found in this project (Figure 2D-F) are comparable to 
those found by Zeevi et al. in human T lymphoid (MOLT-4, IC50 = 365 nM), human B 
lymphoblasts (EB-DN, IC50 = 292 nM), and AML cell line (HL60, IC50 = 365 nM). (138) It is 
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however obvious that the different cell lines show differences in drug sensitivity when 
comparing IC50 values, suggesting a similar variability could be found in AML patients.   
Preliminary results for comparing the metabolic activity of normal healthy lymphocytes and 
AML leukemic blasts (Figure 4) showed a high variance between patient responses, but that 
PBMCs in general tolerated MMF well, with increased proliferation. MOLM13 (IC50 0.048 
µM, Figure 2E) as well as Patient 2 showed higher sensitivity to MMF compared to healthy 
lymphocytes and the AML cell lines HL60 and NB4. (139) Both HL60 and the APL cell line 
NB4 need higher concentrations (0.307 µM and 0.103 µM, respectively) of MMF, to reach 
half of the maximal inhibitory concentration (Figure 2D, F). Nonetheless, the maximal 
inhibited response (bottom plateau in Figure 2F) was slightly higher in NB4 cells than HL60 
and MOLM13 by doses investigated. Thus MMF may have a greater potential in the APL 
subtype of AML patients at concentrations higher than 100 nM MMF, but at these 
concentrations MMF may not have high enough specificity relative to diseased cells. All IC50 
concentrations (Figure 2D – F) are therapeutically attainable concentrations (0.1 – 10 µM). 
(140) However, within the limited time constraints and the interest in proceeding with 
experiments investigating MMFs` attribute in combinational therapy, only two replicates were 
performed. Thus, for statistical evaluation additional experiments will be needed. 
 
5.1.1 Apoptosis induction by MMF 
The effect of MMF in AML cells obtained from WST-1 proliferation based assay is assumed 
to be of cell growth inhibition since all three AML cell lines tested in this project showed 
metabolic inhibition, and hematopoietic cells depend on the de novo guanosine synthesis for 
replicating. However, MMF also induced fragmented nuclear morphology in all three cell 
lines (0.05 µM and higher) investigated. Figure 3B shows slightly higher levels of abnormal 
nuclear morphology in HL60 at higher concentrations (1 µM) compared to MOLM13 and 
NB4. In the two latter cell lines, condensed nuclear morphology dominates over the incidence 
of fragmented nuclei at 0.05 µM MMF, especially in MOLM13 (data not shown). To verify 
that the nuclear morphology assay indicated apoptosis, Annexin-V/PI flow cytometric 
analysis was performed. As HL60 does not expose phosphatidylserine extracellularly during 
apoptosis, (141) Annexin-V cannot be used to label this cell line. Flow cytometric analysis 
was therefore performed only on MOLM13 and NB4. The decrease in percentage of 
metabolically active MOLM13 and NB4 cells was not reflected in a similar decrease in 
viability by Annexin-V/PI, displayed by Figure 5A/C. The lower metabolic activity found by 
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WST-1 conversion in NB4 cells can be due to cell cycle arrest as a response to MMF as a 
large fraction of the cells also show abnormal nuclear morphology and apoptosis by flow 
cytometry (MMF, Figure 5). The treated NB4 cells at these concentrations are therefore 
measured as less apoptotic cells by Annexin-V, which may clarify the difference between the 
results from the metabolism- and viability assay. There is a slightly larger population of viable 
cells (Annexin-V positive) in MMF treated MOLM13 cells accompanied with lower levels of 
metabolically active cells to concentrations between 0.1 – 0.5 µM MMF. If these 
experimental results on MOLM13 cells can be reproduced, they may propose the assumption 
that low concentrations of MMF induce cellular dormancy but not apoptosis, whereas the 
reduced metabolic activity at the two higher doses is due to the cells being apoptotic. (142) 
The same can be found for NB4.  
 
5.1.2 No enhanced anti-leukemic effect from the combination treatment of MMF and 
VPA  
The salvage pathway of guanosine synthesis is to some extent unimportant for T- and B-
lymphocytes. (139) However, about 90% of purines are recycled by the purine salvage 
pathway in humans, thus being still important in other cells. (143) Since VPA treated BNML 
rats showed to have reduced the expression levels of phosphorylated HPRT1 when at late 
stage of the disease, the influence of HPRT1 on leukemic blasts became an interesting topic to 
investigate. Thus VPA and MMF were combined for treatment. The combination of MMF 
with VPA in human AML cells is novel. Sodium valproate and MMF has previously been 
investigated in three renal allograft recipients where valproate was given for seizures. (144) In 
this trial the concentration of MPA in blood decreased in all recipients when concomitantly 
receiving sodium valproate. An increase of 71.4% of the dose was required to maintain the 
area under curve concentration (AUC) of MPA. We found no cooperative effect of the 
combination treatment with MMF and VPA when analyzing for metabolically active or viable 
leukemic cells, on the other hand metabolic activity of cells treated with MMF or MMF 
combined with VPA was more or less identical. However, in Figure 5C the percentage of 
viable MOLM13 cells analyzed by Annexin-V/PI flow cytometry indicates that VPA possibly 
can influence the viability effect of MMF by decreasing its cytotoxicity when combined at 
lower concentrations (0.25 - 1 µM MMF, 0.25 – 1 mM VPA). 
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5.1.3 Alternative Combination Treatments with MMF 
Other combination strategies were investigated briefly for MMF. As the purine salvage 
pathway also contain the adenine phosphoribosyl transferase (APRT) (Figure 1) whose 
activity was associated with an increase in AML patients in the study by Davidson and 
Winter. (56) MMF was combined with the cytotoxic urea analogue hydroxyurea (HU) that 
inhibits the ribonucleotide reductase. (145) This combination treatment (Figure 7A) showed 
no additional effect on reduction of metabolic activity. Analysis of an imbalance in 
ribonucleotide pools by for example purine nucleotide separation by liquid chromatography 
could assess a better prediction of the particular nucleotide concentrations following 
treatment. (145) LND has been reported to increase the cytotoxic effect of conventional 
anticancer agents such as doxorubicin, methotrexate, and etoposide in human and murine 
fibrosarcoma cell lines, but also in other combinations in leukemic cells. (105, 110, 111) 
These chemotherapeutics induce oxidative stress. Lopez-Lazaro observed that for inhibition 
of glycolysis in cancer cells to be efficient, additional drugs affecting the production of ROS, 
H2O2 in particular, would be needed to utilize the hypothesis of the Warburg effect in the 
treatment of cancer cells. (146) As both inhibition targets HK1 and HPRT1were found to be 
down-regulated in an AML study, the combinational effect of both agents was briefly 
investigated by WST-1. (3) An enhanced potentiation was however not observed by the 
combination treatment (Figure 7B).  
 
5.1.4 Investigated potentiation by LND of other chemotherapeutics to induce apoptosis 
and metabolic inhibition 
The anti-leukemic effect on reducing blast metabolic activity and inducing cell death using 
LND as monotherapy was modest in HL60, MOLM13 and NB4 cells (Figure 9, 10) in a 
dose- and time dependent manner. This has also been reported for the sensitivity to VPA. 
(133) Synergism between the two drugs was discovered for HL60 cells in both metabolic- and 
Hoechst 33342 nuclear morphology assays (Figure 14D). Sequence administration of LND 
and VPA was conducted and resulted in compliance to the assumptions of the need for longer 
incubation time and dose dependency for synergistic effect (Figure 12). From this, it appears 
that TP53 depleted blasts might be more responsive to LND, in a dose dependent manner 
compared to cell lines with p53 wild type expression. LND may induce its effect in a p53 
independent manner which can be supported by other findings. (106) Enhanced proliferation 
of NB4 cells was seen at concentrations lower than 100 µM LND (Figure 10A).  The finding 
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that low or median doses of a drug might increase proliferation has previously also been for 
VPA in a subset of primary AML leukemic cells treated ex vivo. (147)  
 
The two drugs 6-mercaptopurine (6-MP) and hydroxyurea (HU) are often used in palliative 
treatment and in older AML patients, but are not associated with sufficient survival outcomes. 
(148) The potential of LND for sensitizing cells to drugs may ensue by increasing the 
efficiency of 6-MP and HU, and was therefore explored (Figure 15). The pilot study showed 
the combinations to be of no beneficial effect on metabolic activity. The antimetabolites 6-MP 
and HU were the dominating drugs leading the cytotoxic effect of the combination with LND. 
Interestingly, the latter combination seemed to induce less growth inhibition in HL60 cells 
than with single drug treatment. The difference between expected additive effect (Bliss 
Independence test) and actual combinatorial effect is however low, and as this experiment 
was performed only once, it is likely that a repeat of this study might result in the loss of this 
effect due to experiment-to-experiment variation. Sub-G1 peaks in LND treated HL60 cells in 
a previous study may support this finding  suggesting LND to protect the cells from HU 
induced S phase arrest, which could be an antagonistic effect also observed by Hoechst 
viability assay. (149) These results should be repeated for a more reliable evaluation. 
5.2 Distinct response to VPA and LND in native AML peripheral blood versus 
bone marrow 
In the primary AML cell experiment with patient derived blasts described in section 4.2.4, 
cells from patient II appeared more sensitive to VPA at lower concentrations and to LND at 
concentrations up to 20 µM, than cells from patient I. But they both follow a similar trend 
where the decrease in percentage of metabolically active cells was lesser at higher drug 
concentrations compared to the decrease in metabolically active cells at lower concentrations 
of both drugs LND and VPA. Thus, higher concentrations of the agents may not be needed to 
achieve response on decreasing the rate of cancer growth in these specific patients. 
Unfortunately, resistance to VPA was observed in the bone marrow derived sample 
comparable to the peripheral blood sample from the same patient (II), whilst an enhanced 
sensitivity to LND was observed. More statistically-valid and quantitative analysis is needed 
for reliable interpretations to be made. However, distinct phenotypes in for example adhesion 
molecule cell surface expression between blood and bone marrow derived from same patient, 
is a subject of increasingly intense investigation. (150)  
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5.3 Validation of HK1 and HPRT1 transient knockdown effecting the 
metabolically activity in HL60, MOLM13 and NB4.   
Due to time constraints, knockdown of HPRT1 was only performed in HL60. The knockdown 
did not affect the measurable effect on metabolic activity in the control (DMSO) nor did it 
increase the effect of MMF suggesting the reduction of HPRT1 alone not to be sufficient to 
affect metabolic activity. Consequently, the effect seen by MMF may not preferably be due to 
inhibition of HPRT1. However, HPRT1 knockdown seemed to sensitize HL60 cells to VPA. 
If this finding can be verified by repeated studies, it may demonstrate that a more direct 
targeting of HPRT1 indeed can increase the responsiveness to VPA. The consideration of 
combining VPA with a different drug with higher specificity to HPRT1 than what MMF 
seems to possess, could potentiate VPA as an anti-leukemic agent in AML patients. (151) 
 
The effect of knockdown of HK1 in HL60 cells did not seem to have a distinguishable effect 
on metabolic activity (Figure 17A). Comparing the results obtained from HL60 with those 
obtained in MOLM13 and NB4 cells (Figure 17B, C), knockdown of HK1 showed to induce 
growth inhibition in control cells in both cell lines.  HK1 knockdown in MOLM13 enhanced 
the sensitivity of VPA and LND, however the results for VPA and control cells were similar 
suggesting no additional effect was obtained by combining VPA and HK1 depletion. For 
NB4, variations in LND treated cells not subjected to HK1 siRNA, as well as the high 
sensitivity for VPA meant no conclusions could be drawn. Whether the potential increased 
effect of LND and VPA by HK1 knockdown found in MOLM13 is due to a decrease in 
number of cells or that the cells present are less metabolically active is difficult to say when 
not combined with additional assays, for example Hoechst viability assay gives an impression 
on whether the reduced fraction can be due to apoptosis induction, in other words fewer cells.  
Because of the potential sensitizing effect of VPA by HK1knockdown in MOLM13 and 
HPRT1 knockdown in HL60, this might suggests that the reduced protein expression 
observed from the VPA treated BNML rat study were of an anti-leukemic effect and not a 
resistance response aiding in disease progression. However, sample size needs to be increased 
for a significant evaluation. 
 
Microscopy was used for the evaluation of transfection efficiency by the examination of AF 
488 positive cells. But since siRNA was still present in the cell suspension, causing high 
background, the distinction between AF 488 positive and negative cells was not obtainable. 
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Hence quantification of positive versus negative transfected cells was not performed. 
Nonetheless, knockdown was assumed to be induced as a difference in VPA +/- HPRT1 
siRNA was observed (Figure 8) and for MOLM13 and NB4 +/- HK1 siRNA (Figure 17). If 
HK1 and HPRT1 are involved in mediating the growth inhibitory effect of LND and MMF, 
respectively, we would expect less sensitivity to LND and MMF in the knockdown cells 
because their proliferation would be less dependent on HK1 and HPRT1. The results obtained 
in this project (Figure 8 and 17) comprise great variation which would need replicative 
studies to clarify whether there is an actual decreasing or increasing sensitivity to LND and 
MMF by HK1 and HPRT1 knockdown. However, from these preliminary results, HK1 does 
not seem to be the only inhibitory mediator of LND anti-leukemic effects in HL60 and 
MOLM13 cells, while HPRT1 does not seem to be pivotal for an anti-proliferative effect of 
MMF in HL0 cells.   
5.4 The effect of Lonidamine and Valproic acid on Hexokinase and other 
signaling pathway proteins 
The ability of VPA to induce apoptosis, cell differentiation and inhibition of proliferation and 
cell cycle progression is suggested to be important for its cytotoxic effect. Nonetheless, VPA 
may also increase superoxide formation as it prevents the flow of electrons through the 
electron transport chain by interacting with biological components such as for example 
superoxide dismutase. (151) The influence of oxidative phosphorylation may obscure the 
results from the conversion of WST-1 salt to formazan, causing the varying measurements 
from the proliferation assay which can be clearly observed in Figure 5A. However, the 
inhibition of HDACs by VPA affects several downstream mechanisms of differentiation, cell 
growth, and apoptosis. (52) The active signaling pathways in AML after a response by VPA 
treatment in the BNML rat model revealed a reduced expression of HK1. Given that the rats 
with leukemia responded to the treatment and that overexpression studies have implicated 
pro-survival role of HK1, we hypothesized that the protein expression of phosphorylated HK1 
would be reduced by VPA in human AML cells lines and may contribute to increase the anti-
leukemic effect of VPA. (3, 152) However, Figure 18 shows that this was not the case in 
HL60, MOLM13, and NB4 AML cells when characterized by Western blotting. We did not 
expect to obtain less expressed HK1 from LND treated samples since LND inhibits this 
enzyme activity and not in particular affects HK1 by reducing its protein expression. As the 
extracted proteins from moribund rats were purified for phosphorylated proteins through 
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affinity chromatography, this was repeated in this project in the attempt to reproduce the 
effect seen in vivo with VPA, only with human AML cell lines in vitro. However, 
phosphorylated protein concentrations that remained after purification procedure were too low 
for further investigation of the extent of phosphorylation by separation on Western blot. Thus 
the determined protein content detected by Western blotting (Figure 18) presented in this 
thesis represents total HK1 protein, and not only the phosphoproteins, suggesting that the 
protein expressed do not have to be biological active. However, studies have shown that the 
detachment of HK1 from VDAC1 proceeds apoptosis. (153) Thus, cytosolic and mitochondria 
fractions of cells could be separated after treatment and investigated for their fractions of HK1 
to provide a closer estimation of active HK1 versus non-active HK1. The in vitro results on 
HK1 protein expression in this thesis were based on 48 hour treatment, whilst the BNML rats 
were treated with VPA for four weeks (five days a week). Thus, the increase of protein 
expression observed might be a consequence of compensation for the inhibitor-mediated 
decrease in HK1 that could act as a regulating factor for the expression of HK1. Since HK2 
also is said to be inhibited by LND, its expression was studied by Western blotting. (135, 136)  
Less differences in HK2 protein expression in treated with LND and VPA was shown for 
HK2 than for HK1. As the antibodies used for detection of HK1 and HK2 were not specific 
for the phosphorylated HK1 and HK2, it is not sure if the expressed proteins resemble the 
actual HK1 and HK2 activity in cells. Nonetheless, the results indicate that the total amount of 
HK2 does not change when exposed to VPA or LND.  
 
The major players of the signaling pathways in apoptosis are a group of zymogenic cysteine 
proteases (caspases). (154) They are present in the cell in an inactive form when not 
stimulated by either the death receptor pathway by tumor necrosis factor family: the extrinsic 
pathway for programmed cell death, or by the mitochondria mediated intrinsic pathway. Pro-
apoptotic agents inhibiting HK1 and HK2 binding to VDAC1 on B-cell chronic lymphocytic 
leukemia was showed to activate the mitochondrial pathway by releasing cytochrome c to the 
cytoplasm. (155) Subsequent involvement of apoptosome formation and activation of the 
initiator caspase 9 does normally proceed. And as previously explained in section 1.5.3, the 
intrinsic caspase-mediated apoptotic pathway may be escaped at abnormal hexokinase 
binding to VDAC1. Figure 19A and quantitative analysis of protein expression through 
Western blotting indicate the opposite downstream signaling from what is proposed by the 
literature where LND is supposed to induce mitochondrial apoptotic signaling pathway. Only 
the addition of VPA alone or combined with LND treated HL60 showed increased expression 
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of cleaved caspase 9 (Figure 19A). The increased intrinsic apoptosis induction through 
enhanced protein expression levels of cleaved caspase 9 can be reflected by the synergistic 
effect as a consequence of inhibited metabolism in HL60 (Figure 14C). Diminished 
expression of cleaved caspase 9 expression following treatment of LND or VPA (MOLM13, 
NB4) may suggest the prevention of apoptosome formation. AKT and ERK are two key 
targets for therapeutic intervention as they are commonly active in acute myeloid leukemia. 
They are two kinases that can subsequently inhibit the enzymatic activity of caspase 9 through 
phosphorylation. (104, 156) Furthermore, the expression of ERK has been shown to be 
enhanced in VPA treated endothelial cells, supporting the increased expression of 
phosphorylated ERK1/2 in Figure 19C. (104) The reduced expression of phosphorylated 
ERK1/2 after treatment with LND may not be adequate to dismiss the possibility that LND 
rather provoke activation of ERK kinase, as previously been observed, but which was 
attenuated when combined with arsenic trioxide. (103) Co-treatment of LND and VPA 
reduced the protein expression on phosphorylated ERK1/2 beyond what was obtained when 
treated with VPA alone. The initiator caspase 8 of the extrinsic apoptosis signaling pathway 
was clearly detected in its cleaved form (Figure 19A) suggesting for TNF stimulation and 
mediated apoptosis though the extrinsic signaling pathway. The pro-apoptotic stimulation of 
TNF-α is an effect that has already been observed to be specific to VPA by Wang et.al. (157) 
This increased expression of pre- apoptotic inducing proteins can be recognized by the 
apoptotic populations formed following treatment shown by flow cytometric analysis (Figure 
13). To determine whether all three drugs, MMF, LND and VPA induce apoptosis rather than 
necrosis in the susceptible cells, a DNA ladder assay could be performed.  
 
The increased expression of p21
WAF1/CIP1 
can be supported by other literature reporting it to be 
modulated by VPA. (55) p21 can induce cell cycle arrest in VPA treated cells which does not 
appear to be p53-dependent, but rather likely due to changes in histone acetylation at the 
promoter of p21. (158) This observation is compatible with the WST-1 proliferation assay 
result described in section 4.2.3, showing an independent response in LND and VPA treated 
TP53 depleted cells (Figure 14C). Furthermore, increased p21
WAF1/CIP1
 expression could 
indicate an arrest in cell cycle progression at G1 and S phase. Detailed investigation of p53 
mediated mechanisms in response for LND-induced effect was beyond the purpose of this 
project. The validation of the suggested cell cycle arrest at G1/S phase could be analyzed by 
flow cytometry using propidium iodide DNA staining.  
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5.5 Preclinical toxicity in mice determined the maximum tolerated dose and its 
toxicity  
The preliminary maximum tolerated dose (MTD) study was performed to evaluate the safety 
of LND and assess the optimal dosing for subsequent therapies. The literature available 
described previously used doses at experimental procedure, ranging from 50 mg/kg to 100 
mg/kg once daily. (159, 160) The route of drug delivery in this thesis was intraperitoneally, 
same as in the literature mentioned. The drug has a low solubility in water, thus may 
precipitate in stomach before absorption when given orally. Because of this low solubility, a 
higher percentage (70%) of the vehicle consisted of PEG300, but was considered safe to use 
confirmed by administering of vehicle only in two control mice. (161) The primary dose at 50 
mg/kg/day was supposed to be the lowest dose of the planned doses administered in this study 
(50 mg/kg, 75 mg/ and 100 mg/kg).  But 5 minutes after first injection they already appeared 
lethargic as they did not move around in cage and quickly resettled when disturbed by 
opening of the cage. Following 24 hours, an unacceptable toxicity was observed by weight 
loss of 9.61% (average of three mice) (Figure 20B). Ruffled fur due to piloerection and loss 
of body weight were signs assumed to be due to dehydration mimicking LND interference 
with mitochondria function, affecting the energy metabolism by inhibition of cellular 
respiration. For a quick recover 0.9% sodium chloride solution was administered 
subcutaneously. The dose was reduced to 25 mg/kg/day LND, which resulted in weight loss 
of just above 7-8% (Figure 20A) and no signs of phenotypic toxicities. Since LND is 
intended to be combined with VPA in mice bearing subcutaneously implanted leukemia cells, 
the study was not continued to reach fully 10% loss in body weight. Whether LND at 25 
mg/kg/day is of true therapeutic advantage can be assessed in further studies with tumor 
studies in mice. However, this study showed that the MTD of i.p. administered LND is 25 
mg/kg for female mice over a period of 5-day dosing and is safe to mice with no observable 
side effects. The MTD in this study was lower than what had previously been used in the 
literature that we based our doses on. But in one of the studies the mice died right after 
completed 3 hour experiment (100 mg/kg). (162) An anti-cancer effect of concentrations with 
LND < 50 mg/kg has been observed, but with only few experiments performed. (163)  
5.6 Conclusions and Future perspectives 
The in vitro metabolism inhibiting effect of MMF indicated that the drug may have a role in 
the treatment of AML, but the need for combination treatment is apparent for an enhanced 
P a g e  | 69 
 
69 
 
efficiency among AML patient samples. Nonetheless, no toxic effect on PBMC metabolism 
was obtained. LND exhibited modest cytotoxicity against all AML cell lines tested in this 
thesis. Significant synergistically inhibited metabolism in HL60 cells was demonstrated in 
vitro by WST-1 assay and supported by reduced pERK1/2 expression through Western blot 
analysis, suggesting that combination of HDACi VPA with HK1 inhibitor LND could be 
beneficial in the treatment of AML expressing depleted p53, and is to our knowledge the first 
report of LND and VPA combination efficacy in AML study.  A pilot preliminary toxicity 
study showed 25 mg/kg/day for 5 days of LND in NOD/scidILrgamma female mice through 
i.p. administration to be well tolerated. These data may assist in the design and interpretation 
of additional preclinical investigations of LND combined with VPA in mice with 
subcutaneously implanted leukemic cells.  
 
To not wrongly interpret the anti-proliferative effect observed by MMF and LND treatment, 
measurement of the tritiated thymidine (
3
H) incorporation should be considered as a more 
specific method for the evaluation of cell proliferation. This will also be important since 
WST-1 conversion by cellular oxidoreductase activity can differ among cell lines due to 
varied extracellular superoxide content and by the interference of VPA in the formation of 
ROS. Besides, the examination of the cells` stage of differentiation should be assessed by 
immunophenotyping. It would also be interesting to mimic the conditions in the leukemic 
bone marrow by modified culture medium reflecting the concentrations of key metabolites 
found in bone marrow and explore whether experiments under hypoxia (2% O2) show other 
results from combination treatment.  
 
Inhibition of cancer cells’ favor of accumulating energy production by cytosolic glycolysis for 
the anabolic processes may be shunted towards other energetic processing pathways such as 
catabolic oxidative pathways within the mitochondria. Thereby might driving cancer cells on 
glutamine dependency, regulated by c-myc which again, according to The Champion ChiP 
Transcription Factor Search Portal, regulates the transcription of HK1. However, AML blasts 
holding isocitrate dehydrogenase (IDH) mutations would likely benefit of a shift towards 
mitochondria respiration with glutamine metabolism as IDH mutations result in enzyme 
activity utilizing glutamine to its profit for cancer growth induction. (73)  
 
We have sought to determine signaling cascades mediated by LND that sensitizes leukemic 
blasts to other chemotherapeutic agents when combined. Plausibly and also demonstrated by 
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other studies, is the greater extent of inhibition of HK1 and HK2 by LND related to an 
elevated aerobic glycolysis. (164) This hypothesis can however not be reflected by the 
comparison of HK1 and HK2 protein expression level by Western blot analysis (Figure 15) 
and growth inhibition (Figure 7A) as the protein expression level increased with enhanced 
anti-metabolic activity effect. Treating IPC-81 cells derived from the BNML rat model 
followed by immobilized metal affinity chromatography (IMAC) prior to investigation of 
HK1 expression level by immunoblot or 2-dimensional gel-electrophoresis, exposing the 
altered isoelectric point of the phosphorylated proteins, could closer reflect the experimental 
finding of reduced expression of HK1 in the BNML-study.  
 
For future combination experiments it would be interesting to see whether the effect on 
inhibition of cytosolic glycolysis energy production by LND could be utilized in the 
advantage of a cytotoxic effect when combined with a H2O2 producing agent such as for 
example Bortezomib that is well tolerated in elderly patients. (165) As a prominent result in 
this work, we demonstrated that HPRT1 and HK1 can have a pivotal role in sensitizing VPA 
in AML cells. This was particularly demonstrated by HPRT1 knockdown in HL60 cells and 
HK1 knockdown in MOLM13 and NB4 cells, for VPA treatment. Quantitative real-time PCR 
(qRT-PCR) and Western blot could be used for the evaluation of a successful knockdown or 
not. Nonetheless, we speculate that the ability of VPA to induce cell growth inhibition is 
likely to be potentiated by the combination of VPA with more specific HK1 and HPRT1 
targeting drug. The quantification of HK1 and HPRT1 after transient knockdown should be 
validated by Western blot analysis. Furthermore, siRNA knockdown to HK1 and HPRT1 in 
PBMCs will reveal whether this strategy can be feasible in multicellular organism.  
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